



(22) Date de dépôt/Filing Date: 1997/10/30

(41) Mise à la disp. pub./Open to Public Insp.: 1998/04/30

(45) Date de délivrance/Issue Date: 2007/05/22

(30) Priorité/Priority: 1996/10/30 (JP288074/1996)

(51) Cl.Int./Int.Cl. *C07D 491/22* (2006.01),
C07D 209/42 (2006.01), *C07D 217/26* (2006.01),
C07D 491/14 (2006.01), *C07D 491/147* (2006.01),
C07D 491/20 (2006.01)


(72) Inventeurs/Inventors:
KAWAGUCHI, TAKAYUKI, JP;
NOMURA, SUMIHIRO, JP;
TSUJIHARA, KENJI, JP

(73) Propriétaire/Owner:
TANABE SEIYAKU CO., LTD., JP


(74) Agent: KIRBY EADES GALE BAKER

(54) Titre : ESTERS HYDROXY-2-INDOLIDINYLBUTYRIQUES AVEC SUBSTITUTION EN 2, DE TYPE S, ET METHODE POUR LES PREPARER

(54) Title: S TYPE 2-SUBSTITUTED HYDROXY-2-INDOLIDINYLBUTYRIC ESTER COMPOUNDS AND PROCESS FOR PREPARATION THEREOF



[II]




[I]

(57) Abrégé/Abstract:


The present invention is directed to a process for preparing S type 2-substituted hydroxy-2-indolidinylbutyric ester compound [II]: (see formula II) wherein R^0 is a residue of nitrogen-containing fused heterocyclic carboxylic acid having absolute configuration of "R" (in which the nitrogen atom is protected), R^1 and R^2 are lower alkyl groups, and E is an ester residue. The compound of the present invention is useful as an intermediate for preparing camptothecin derivatives having antitumor activities, which comprises 2-ethylating 2-substituted hydroxy-2-indolidinylacetic ester compound [I]: (see formula I) wherein R^0 , R^1 , R^2 and E are as defined above.

ABSTRACT

The present invention is directed to a process for preparing S type 2-substituted hydroxy-2-indolidinylbutyric ester compound [II]:



wherein R^0 is a residue of nitrogen-containing fused heterocyclic carboxylic acid
 5 having absolute configuration of "R" (in which the nitrogen atom is protected),
 R^1 and R^2 are lower alkyl groups, and E is an ester residue. The compound of
 the present invention is useful as an intermediate for preparing camptothecin
 derivatives having antitumor activities, which comprises 2-ethylating 2-substituted
 hydroxy-2-indolidinylacetic ester compound [I]:




10 wherein R^0 , R^1 , R^2 and E are as defined above.

S TYPE 2-SUBSTITUTED HYDROXY-2-INDOLIDINYLBUTYRIC ESTER
COMPOUNDS AND PROCESS FOR PREPARATION THEREOF


This invention relates to an S type 2-substituted hydroxy-2-indolidinylbutyric ester compound and a process for the preparation thereof.

5 More particularly, it relates to an S type 2-substituted hydroxy-2-indolidinylbutyric ester compound which is useful as an intermediate for preparing camptothecin derivatives having antitumor activities and a process for preparing said compound in high yield and in high stereoselectivity.


There is known a process for preparing camptothecin derivatives having
10 antitumor activities by Friedlaender reaction (cf. EP-A-540099, EP-A-296597, JP-A-6-87746, WO 90/03169, EP-A-418099), wherein it has been investigated to find processes for preparing S type 4-hydroxypyranoidindolidine compounds of the formula [VIII] which are important as an intermediate:



It has been reported, for example, in EP-A-220601 that an S type 2-
15 [(R)-N-tosyl-propyloxy]-2-indolidinylbutyric ester compound of the formula [XXI]:



may be prepared by brominating at the 2-position of a 2-indolidinylacetic ester compound of the formula [XX]:




and reacting the resultant product with an (R)-N-tosylproline and further ethylating at the 2-position of the reaction product, and further that a
5 camptothecin derivative is prepared from said compound via an S type 4-hydroxypyranoidindoline compound [VIII].


However, according to this process, the desired S type 2-[(R)-N-tosylprolyloxy]-2-indolidinylbutyric ester compound [XXI] is merely obtained in an amount of 2.6-4.6 times larger (44-64% d.e.) than that of a diastereomer
10 having an absolute configuration of "R" at the 2-position which is simultaneously prepared, and the S type compound is isolated therefrom in a further lower yield, only 56%, by a fractional recrystallization [cf. Organic Synthetic Chemistry, vol. 49, No. 11, pp. 1013-1020, 1991].

This invention provides an S type 2-substituted hydroxy-2-indolidinylbutyric ester compound useful as an intermediate for preparing camptothecin derivatives in a high yield and in a high stereoselectivity.

According to this invention, the desired S type 2-substituted hydroxy-2-indolidinylbutyric ester compound of the formula [II]:



can be prepared by reacting a 2-halo-2-indolidinylacetic ester compound of the formula [III]:




wherein X is a halogen atom, R¹ and R² are each a lower alkyl group, and E is an ester residue, with an R type nitrogen-containing fused heterocyclic carboxylic acid compound of the formula [IV]:



wherein R^o is a residue of a nitrogen-containing fused heterocyclic carboxylic acid having an absolute configuration of "R" which is obtained by removing a

hydroxy group from the carboxyl group of said carboxylic acid compound (in which the nitrogen atom contained in the residue is protected) or a salt thereof to give a 2-substituted hydroxy-2-indolidinylacetic ester compound of the formula [I]:



wherein R^0 , R^1 , R^2 and E are as defined above, and then ethylating the 2-position of the resultant compound [I].


10 The process of this invention is characteristic in that the 2-substituted hydroxy-2-indolidinylacetic ester compound [I] is sterically bulky at the acetal moiety and has a sterically bulky substituent containing an optically active nitrogen-containing fused heterocyclic ring at the 2-position thereof and hence it is

15 ethylated with high yield and high stereoselectivity at the 2-position, and thereby the desired S type 2-substituted hydroxy-2-indolidinylbutyric ester compound [II] is obtained in a high selectivity such as 9 times or more higher (80% d.e. or more) than the diastereomer having an absolute configuration of "R" at the 2-position. Particularly, when the group "Y" in the substituent R^0 in the

20 compound [I] is a 4-nitrophenylsulfonyl group or a 4-biphenyl sulfonyl group, the desired compound is obtained in much higher stereoselectivity of 20 times (90% d.e.) or 15.2 times (88% d.e.) higher, respectively and in much higher isolation yield of 75% or 76%, respectively.

The R type nitrogen-containing fused heterocyclic carboxylic acid compound [IV] in this invention means a compound having a carboxyl group bound to a nitrogen-containing fused heterocyclic ring (the nitrogen atom contained in said compound is protected), and the carbon atom bound with the carboxyl group has an absolute configuration of "R", and the nitrogen-containing fused heterocyclic ring includes a benzene-fused nitrogen-containing heterocyclic ring, for example, a tetrahydroisoquinoline ring, a tetrahydroquinoline ring, a dihydroquinoline ring, or an indoline ring.

Suitable example of the nitrogen-containing fused heterocyclic carboxylic acid compound having an absolute configuration of "R" is a compound of the formula [XIX]:



wherein n is 0 or 1, and Y is a substituted or unsubstituted arylsulfonyl group or a lower alkylsulfonyl group.

The above compound [XIX] wherein n is 1 means an N-substituted-1,2,3,4-tetrahydro-3-ylquinolinecarboxylic acid, and the compound [XIX] wherein n is 0 means an N-substituted 2-indolinecarboxylic acid. The substituent "Y" on the nitrogen atom of the above compound [XIX] includes a phenylsulfonyl, naphthylsulfonyl or biphenylsulfonyl group (which may optionally be substituted by a member selected from a nitro group, a lower alkyl group, a lower alkoxy group, a cycloalkyl group, a halogen atom, or a thienyl

group), or a lower alkylsulfonyl group, for example, a phenylsulfonyl group, a tosyl group, a 2,4,6-trimethylphenylsulfonyl group, a 4-nitrophenylsulfonyl group, a 4-chlorophenylsulfonyl group, a 4-methoxyphenylsulfonyl group, a 4-cyclohexylphenylsulfonyl group, a 4-(3-thienyl)phenylsulfonyl group, a 2-naphthylsulfonyl group, a 4-biphenylsulfonyl group, a methylsulfonyl group, and an ethylsulfonyl group.

Among the above, preferred compounds include a compound [XIX] wherein the substituent "Y" on the nitrogen atom is a tosyl group, a 2-naphthylsulfonyl group, a 2,4,6-trimethylphenylsulfonyl group, a 4-biphenylsulfonyl group, or a 4-nitrophenylsulfonyl group and n is 1, and a compound [XIX] wherein the substituent "Y" on the nitrogen atom is a tosyl group and n is 0. Particularly preferred compounds include a compound [XIX] wherein the substituent "Y" on the nitrogen atom is a 4-biphenylsulfonyl group or a 4-nitrophenylsulfonyl group and n is 1.

The R^1 and R^2 are a lower alkyl group, such as a methyl group, an ethyl group, a propyl group, an isopropyl group, an n-butyl group, an isobutyl group; X is a halogen atom such as chlorine, bromine, iodine. The E includes any conventional ester residues, for example lower alkyl groups such as a methyl group, an ethyl group, a propyl group, an isopropyl group, an n-butyl group, or an isobutyl group. Among them, preferred groups are R^1 and R^2 being a methyl group, X being a chlorine atom or a bromine atom, and E being a methyl group or an ethyl group.

The reaction of the 2-halo-2-indolidinylacetic ester compound [III] and the R type nitrogen-containing fused heterocyclic carboxylic acid compound [IV] or a salt thereof is carried out in a suitable solvent.

The salt of the R-type nitrogen-containing fused heterocyclic carboxylic acid compound [IV] includes an alkali metal salt (e.g. potassium salt, sodium salt),
5 an alkaline earth metal salt (e.g. magnesium salt, calcium salt).

The reaction of the 2-halo-2-indolidinylacetic ester compound [III] and the R type nitrogen-containing fused heterocyclic carboxylic acid compound [IV] or a salt thereof is carried out in the presence or absence of an acid scavenger.
10 Suitable examples of the acid scavenger are inorganic bases, such as an alkali metal hydride (e.g. lithium hydride, sodium hydride, potassium hydride), an alkali metal amide (e.g. lithium amide, sodium amide, potassium amide), an alkali metal carbonate (e.g. sodium carbonate, potassium carbonate), an alkali metal hydrogen carbonate (e.g. sodium hydrogen carbonate, potassium hydrogen carbonate), an
15 alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, lithium hydroxide), and organic bases, such as an alkali metal alkoxide (e.g. sodium ethoxide, potassium tertbutoxide), an alkali metal alkylamide (e.g. lithium diisopropylamide), a trialkylamine (e.g. triethylamine, trimethylamine), an N,N-dialkylaniline (e.g. N,N-dimethylaniline), 1,8-diazabicyclo[5.4.0]undeca-7-ene.

20 The solvent used in the reaction includes any conventional solvent which does not have an effect on the reaction, and suitable examples are an amide type solvent (e.g. dimethylformamide, dimethylacetamide), an ether solvent (e.g. tetra

hydrofuran, dimethyl ether, dioxane). The reaction is usually carried out at a temperature of from 20 to 100°C, preferably from 50 to 70°C.

The subsequent 2-ethylation of the 2-substituted hydroxy-2-indolidinyllactic ester compound [I] is carried out in a suitable solvent in the presence of an acid scavenger.


The ethylating agent is preferably an ethyl halide (e.g. ethyl iodide, ethyl bromide), more preferably ethyl iodide. The acid scavenger is the same agent as mentioned above for the reaction of the 2-halo-2-indolidinyllactic ester compound [III] and the R type nitrogen-containing fused heterocyclic carboxylic acid compound [IV] or a salt thereof, and particularly a preferred agent is sodium hydride.

The solvent used in the reaction includes any conventional solvent which does not affect reaction, and suitable examples include an amide type solvent (e.g. dimethylformamide, dimethylacetamide), a sulfoxide solvent (e.g. dimethylsulfoxide), an ether solvent (e.g. tetrahydrofuran, dioxane, dimethyl ether), an aromatic hydrocarbon solvent (e.g. toluene, xylene, benzene, chlorobenzene), or a mixture thereof, and a particularly preferred solvent is a mixture of dimethylacetamide and toluene. The reaction is usually carried out at a temperature of from -10 to 50°C, particularly preferably at a room temperature.

The desired compound [III] in a crude form thus obtained can easily be purified by recrystallization to give a highly purified compound [III].


The S type 2-substituted hydroxy-2-indolidinylbutyric ester compound [II] thus obtained is subjected to a catalytic reduction to reduce the

cyano group thereof and then subjected to alkanoylation to give an S type 2-substituted hydroxy-2-(6-substituted aminomethylindolidinyl)butyric ester compound of the formula [V]:




wherein R^3 is a lower alkanoyl group, and other symbols are as defined above, and the resultant product is subjected to nitrosation reaction and rearrangement to give an S type 2-substituted hydroxy-2-(6-substituted hydroxymethylindolidinyl)-butyric ester compound of the formula [VI]:

10




wherein R^0 , R^1 , R^2 , R^3 and E are as defined above. The compound [VI] is then subjected to an intramolecular cyclization reaction, and thereafter or at the same time as the cyclization reaction, the acetal group thereof is converted into a ketone group to give an S type 4-substituted hydroxypyranoidindoline compound of the formula [VII]:

20




wherein R^0 is as defined above.

The above compound [VII] is subjected to Friedlaender reaction together with an o-acylaniline compound of the formula [XIV]:




wherein the groups R^5 - R^9 are each a hydrogen atom or an optionally protected
 5 substituent, in a conventional manner to give a camptothecin compound having a substituent on the 20-hydroxy group of the formula [XV]:



wherein R^0 , R^5 to R^9 are as defined above,


and the compound [XV] is subjected to removal of R^0 group and further, when the groups R^5 - R^9 are protected, subjected to removal of the protecting group, and
 10 further optionally to conversion into a salt thereof to give a camptothecin compound of the formula [XVI]:

11



5 wherein the groups R^{51} - R^{91} are each a hydrogen atom or an unprotected substituent, or a salt thereof.

It is assumed that in the above intramolecular cyclization reaction of the S type 2-substituted hydroxy-2-(6-substituted hydroxymethylindolidinyl)butyric ester compound [VI], there is produced a compound of the following formula:




10 wherein R^0 , R^1 and R^2 are as defined above.

The camptothecin compound [XVI] or a salt thereof may also be prepared by a process comprising the following steps:

(a-1) subjecting the S type 4-substituted hydroxypyranoidindoline compound [VII] to removal of the group R^0 , or


15 (a-2) subjecting the S type 2-substituted hydroxy-2-(6-substituted hydroxymethylindolidinyl)butyric ester compound [VI] to an ester hydrolysis to give an S type 2-hydroxy-2-(6-hydroxymethylindolidinyl)butyric acid compound of the formula [IX]:

12



5 wherein R^1 and R^2 are as defined above, subjecting the compound [IX] to an intramolecular cyclization reaction and thereafter or simultaneously with the cyclization reaction converting the acetal group thereof into a ketone group, and further optionally converting the product into a salt thereof to give an S type 4-hydroxypyranoidindoline compound of the formula [VIII]:


10



or a salt thereof,

15 (b) subjecting the compound [VIII] to Friedlaender reaction together with an o-acylaniline compound [XIV] in a usual manner to give a camptothecin compound of the formula [XVII]:

20



wherein R^5 to R^9 are as defined above,

(c) subjecting the compound [XVII] to removal of the protecting group of the groups R^5 - R^9 , when these groups contain a protecting group, and


further

(d) optionally converting the product into a salt thereof.

Alternatively, the camptothecin compound [XVI] or a salt thereof may be prepared by a process comprising the following steps:

5 (i) subjecting the S type 2-substituted hydroxy-2-(6-substituted hydroxymethylindolidinyl)butyric ester compound [VI] to an ester hydrolysis to give an S type 2-hydroxy-2-(6-hydroxymethylindolidinyl)butyric acid compound [IX] or a salt thereof,

10 (ii) subjecting the compound [IX] to an intramolecular cyclization reaction and further optionally converting the product into a salt thereof to give an S type 4-hydroxypyranoidindoline compound of the formula [X]:




15 wherein R¹ and R² are as defined above, or a salt thereof,

(iii) reacting the compound [X] with a lower alkanolic acid of the formula [XI]:



20 wherein R⁴ is a lower alkanoyl group, or a reactive derivative thereof to give an S type 4-alkanoyloxypyranoidindoline compound of the formula [XII]:


14



[XII]

5 wherein R^1 , R^2 and R^4 are as defined above,


(iv) converting the acetal group of said compound [XII] into a ketone group to give an S type 4-alkanoyloxypyranoindolidine compound of the formula [XIII]:



[XIII]

10 wherein R^4 is as defined above,

(v) subjecting the compound [XIII] to Friedlaender reaction together with an o-acylaniline compound [XIV] in a usual manner to give a camptothecin compound having a substituent on the 20-hydroxy group of the formula [XVIII]:



[XVIII]

20 wherein R^4 to R^9 are as defined above,

(vi) subjecting the compound [XVIII] to removal of the group R^4 and further to removal of the protecting group of the groups R^5 - R^9 , when these

groups contain a protecting group, and further

(vii) optionally converting the product into a salt thereof.

In the above compounds, the groups $R^5 - R^9$ include any substituents like those in known camptothecin derivatives (cf. for example, EP-A-540099, EP-A-296597, JP-A-6-228141, WO 90/03169, EP-A-418099) as well as in the camptothecin derivatives as disclosed in European Patent Publication Nos. 757049 and 781781. For example, they include the following groups:

(a) the adjacent two groups among the $R^5 - R^9$ combine to form a straight chain or branched chain alkylene group having 2 to 6 carbon atoms, or are both a hydrogen atom, and one of the remaining groups is $-Q_q-Alk_p-R^{10}$, and other two of the remaining groups are a hydrogen atom, a substituted or unsubstituted lower alkyl group, or a halogen atom,

(b) the adjacent two groups among the $R^5 - R^9$ combine to form a straight chain or branched chain alkylene group having 2 to 6 carbon atoms, and any one carbon atom in the alkylene group is substituted by a group of the formula: $-Q_q-Alk_p-R^{10}$, and the remaining three groups of the $R^5 - R^9$ are a hydrogen atom, a substituted or unsubstituted lower alkyl group, or a halogen atom,

in the above (a) and (b), one or two methylene groups in the alkylene group may be replaced by $-O-$, $-S-$ or $-NH-$,

Q is $-O-$ or $-NH-$,

Alk is a straight chain or branched chain alkylene group having 1 to

6 carbon atoms, which may optionally be interrupted by an oxygen atom,

R^{10} is a protected amino group, a protected lower alkylamino group, a protected piperazino group, or a protected hydroxy group,

p and q are both 0 or 1, or when p is 1, q is 0.

5 The R^{51} - R^{91} are groups derived from R^5 - R^9 by removing the protecting group, specifically the groups as defined for R^5 - R^9 wherein the group R^{10} is a group obtained by removing the protecting group, that is, the group R^{10} being an amino group, a lower alkylamino group, a piperazino group, or a hydroxy group.

10 Preferred combinations of the groups R^{51} - R^{91} are as follows:

(i) R^{71} is 3-aminopropoxy, R^{51} is ethyl, and R^{61} , R^{81} and R^{91} are each hydrogen atom,

(ii) R^{51} is piperazinomethyl, R^{61} and R^{91} are each hydrogen atom, and R^{71} and R^{81} combine to form ethylenedioxy,

15 (iii) R^{51} is aminomethyl, R^{71} and R^{81} combine to form ethylenedioxy, and R^{61} and R^{91} are each a hydrogen atom,

(iv) R^{51} is aminomethyl, R^{71} and R^{81} combine to form methylenedioxy, and R^{61} and R^{91} are each a hydrogen atom,

(v) R^{61} is amino, and R^{51} , R^{71} , R^{81} and R^{91} are each a hydrogen atom,

20 (vi) R^{51} and R^{61} combine to form amino-substituted trimethylene, R^{71} is methyl, R^{81} is fluorine atom, and R^{91} is a hydrogen atom,

(vii) R⁵¹ and R⁶¹ combine to form trimethylene, R⁷¹ is 3-aminopropoxy, R⁸¹ and R⁹¹ are each a hydrogen atom,

(viii) R⁷¹ is 3-aminopropyloxy, and R⁵¹, R⁶¹, R⁸¹ and R⁹¹ are each a hydrogen atom.

5 The salt of the S type 4-hydroxypyranoidindoline compound [VIII], S type 2-hydroxy-2-(6-hydroxymethylindolindinyl)butyric acid compound [IX] or S type 4-hydroxypyranoidindoline compound [X] includes an alkali metal salt (e.g. sodium salt, lithium salt), and the salt of the camptothecin compound [XVI] includes a salt with an inorganic acid (e.g. hydrochloride, sulfate) or a salt with
10 an organic acid (e.g. oxalate, tosylate).

 In the above process for the preparation of a camptothecin compound, the reduction and alkanoylation of the S type 2-substituted hydroxy-2-indolindinylbutyric ester compound [II] are carried out in a suitable solvent. The reduction is usually carried out using a catalyst (e.g. RaneyTM nickel) under hydrogen atmosphere at room temperature to 60°C. The
15 alkanoylation is usually carried out using a conventional alkanoylating agent (e.g. a lower alkanolic acid, a lower alkanolic halide, a lower alkanolic acid anhydride) at room temperature to 60°C. The solvent to be used in these reactions includes a lower alkanolic acid anhydride (e.g. acetic anhydride), a
20 lower alkanolic acid (e.g. acetic acid), or a mixture of them. When a lower alkanolic acid anhydride, a lower alkanolic acid, or a mixture of them is used in the reduction reaction, they may be used also as an alkanoylating agent, and in

such a case, the reduction and the alkanoylation can proceed in a single step.

The nitrosation and rearrangement of an S type 2-substituted hydroxy-2-(6-substituted aminomethylindolidinyl)butyric ester compound [V] can be carried out by a similar method to that disclosed in Journal of Medicinal Chemistry, vol. 23, pp. 554-560 (1980) in a suitable solvent. The nitrosation is carried out under an acidic condition with a conventional nitrosating agent (e.g. sodium nitrite, potassium nitrite) at 0°C. The solvent to be used in this reaction includes a lower alkanolic acid anhydride (e.g. acetic anhydride), a lower alkanolic acid (e.g. acetic acid), or a mixture of them.

The subsequent rearrangement reaction can be carried out by heating the product obtained by the above nitrosation at a temperature of 60 to 70°C. The solvent to be used in the rearrangement reaction includes a halogenated hydrocarbon (e.g. carbon tetrachloride, chloroform, methylene chloride), an ester solvent (e.g. ethyl acetate), a non-aromatic hydrocarbon solvent (e.g. n-hexane), an aromatic hydrocarbon solvent (e.g. toluene).

The ester hydrolysis of the S type 2-substituted hydroxy-2-(6-substituted hydroxymethylindolidinyl)butyric ester compound [VI] can be carried out by a conventional method for the ester hydrolysis in a suitable solvent in the presence of a base.

The base to be used in the ester hydrolysis includes inorganic bases, such as an alkali metal hydroxide (lithium hydroxide, sodium hydroxide, potassium hydroxide), an alkaline earth metal hydroxide (e.g. calcium hydroxide), an ammonium hydroxide, an alkali metal carbonate (e.g. sodium

carbonate, potassium carbonate), an alkali metal hydrogen carbonate (e.g. sodium hydrogen carbonate), organic bases, such as an alkali metal alkoxide (e.g. sodium ethoxide, sodium methoxide), an alkali metal phenoxide (e.g. sodium phenoxide), a mono-, di- or tri-lower alkylamine (e.g. methylamine, ethylamine, N,N-dimethyl-1,3-propanediamine, trimethylamine, triethylamine).

The solvent includes an alcohol solvent (e.g. methanol, ethanol, propanol, isopropanol, butanol), a sulfoxide solvent (e.g. dimethylsulfoxide), a halogenated hydrocarbon solvent (e.g. methylene chloride), an ether solvent (e.g. tetrahydrofuran), or a mixture of the organic solvent with water. When the base is a liquid, it may also be used as a solvent. The reaction is preferably carried out at a temperature of 0 to 50°C, more preferably at room temperature.

When the intramolecular cyclization reaction of an S type 2-substituted hydroxy-2-(6-substituted hydroxymethylindolyl)butyric ester compound [VI] or an S type 2-hydroxy-2-(6-hydroxymethylindolyl)butyric acid compound [IX] or a salt thereof and the conversion of the acetal group into a ketone group are carried out simultaneously, they can be carried out in a single step by treating the compound with a suitable acid. The acid includes an inorganic acid (e.g. hydrochloric acid, sulfuric acid), an organic acid (e.g. trifluoroacetic acid), and a mixture of them with water. The acid may also be used as a solvent.

On the other hand, when the intramolecular cyclization reaction of an S type 2-substituted hydroxy-2-(6-substituted hydroxymethylindolyl)-

butyric ester compound [VI] or an S type 2-hydroxy-2-(6-hydroxymethyl-indolidinyl)butyric acid compound [IX] or a salt thereof is first carried out and thereafter the conversion of the acetal group into a ketone group is carried out, the reactions can be carried out by treating the compound with an acid (e.g. acetic acid, citric acid) weaker than the acid used in the above single step reaction and then treating the resultant product with the same stronger acid as used in the above single step reaction. For example, when the S type 2-hydroxy-2-(6-hydroxymethyl-indolidinyl)butyric acid compound [IX] or a salt thereof is treated with a weaker acid, there is obtained an S type 4-hydroxypyranoidindoline compound [X], which is converted into an S type 4-hydroxypyranoidindoline compound [VIII] by treating it with a stronger acid.

The reaction of an S type 4-hydroxypyranoidindoline compound [X] or a salt thereof with a lower alkanoic acid [XI] or a reactive derivative thereof can be carried out in the presence of a base.

The lower alkanoic acid [XI] includes, for example, acetic acid, and the reactive derivative thereof includes an acid anhydride (e.g. acetic anhydride), an acid halide (e.g. acetic chloride), an activated ester (e.g. p-nitrophenyl ester). The base includes an alkali metal hydride (e.g. sodium hydride, potassium hydride), an alkali metal carbonate (e.g. sodium carbonate, potassium carbonate), an alkali metal hydrogen carbonate (e.g. sodium hydrogen carbonate, potassium hydrogen carbonate), pyridine, and 4-N,N-dimethylaminopyridine. The reaction is usually carried out at a temperature of 0 to 50°C, preferably at room temperature.

The subsequent conversion of the acetal group of an S type 4-substituted hydroxypyranoidindoline compound [XII] into a ketone group can be carried out by treating the compound with a suitable acid. The acid may be the same acid as used in the case of carrying out the intramolecular cyclization reaction of an S type 2-substituted hydroxy-2-(6-substituted hydroxymethyl-indolidinyl)butyric acid compound [VI] or an S type 2-hydroxy-2-(6-hydroxymethylindolidinyl)butyric acid compound [IX] or a salt thereof and the conversion of the acetal group into a ketone group in a single step.

The reaction of an S type 4-substituted hydroxypyranoidindoline compound [VII], an S type 4-hydroxypyranoidindoline compound [VIII] or a salt thereof, or an S type 4-substituted hydroxypyranoidindoline compound [XIII] with an o-acylaniline compound [XIV] can be carried out by the known Friedlaender reaction [cf. Organic Reactions, vol. 28, pp. 37-202, John Wiley & Sons, Inc., New York (1982)].

The 4-substituted hydroxypyranoidindoline compound [VII] and 4-alkanoyloxypyranoidindoline compound [XIII] are more stable than an S type 4-hydroxypyranoidindoline compound [VIII] or a salt thereof and further have less effect on decomposition of o-acrylaniline compound [XIV] during the Friedlaender reaction and thereby can reduce the undesirable by-production of contaminating impurities, and hence, those compounds are favorably used in the reaction with a smaller amount of the o-acylaniline compound [XIV], with simple post-reaction treatment such as purification and can give the desired camptothecin compounds [XVI] or a salt thereof in a higher yield.

Moreover, the 4-alkanoyloxypyranoidindolidine compound [XIII] has a molecular weight much smaller than that of the 4-substituted hydroxypyranoidindolidine compound [VII], and hence, it can be used in the Friedlaender reaction in a smaller amount with a smaller reaction vessel.


5 The removal of the protecting groups contained in the groups $R^5 - R^9$ can be carried out by a conventional method suitable to the protecting groups contained therein. For example, when the amino protecting group is a benzyloxycarbonyl group, it can be removed by catalytic reduction in the presence of palladium-carbon in a suitable solvent (e.g. tetrahydrofuran,
10 methanol), and when the amino protecting group is a tert-butoxycarbonyl group, it can be removed by treating it with an acid (e.g. hydrochloric acid, trifluoroacetic acid) in a suitable solvent (e.g. tetrahydrofuran, methanol, dioxane, methylene chloride).

 The removal of the residue R^0 from an S type 4-substituted hydroxypyranoidindolidine compound [VII] or from a camptothecin compound having 20-
15 substituted hydroxy group [XV] can be carried out by a conventional ester hydrolysis in the presence of a base in a suitable solvent. The base and solvent are the same as those used in the ester hydrolysis of an S type 2-substituted hydroxy-2-(6-substituted hydroxymethylindolidinyl)butyric ester compound
20 [VI]. The reaction may be carried out under cooling, at room temperature, or with heating.

Besides, the removal of the group R^4 from the camptothecin

compound having 20-alkanoylated hydroxy group [XVIII] can be carried out in the same manner as in the ester hydrolysis of an S type 2-substituted hydroxy--2-(6-substituted hydroxymethylindolidinyl)butyric ester compound [VI] or in the removal of the residue R^o from an S type 4-substituted hydroxypyranoin-
5 indolidine compound [VII] or from a camptothecin compound having 20-substituted hydroxy group [XV].

The o-acylaniline compound [XIV] to be used in the above condensation reactions can be prepared by a process as shown in the following reaction scheme-1:

Reaction Scheme-1

wherein R^5 to R^9 are as defined above.

That is, a hydroxyl compound [XXII] is treated with an oxidizing agent (e.g. activated manganese dioxide, pyridinium dichromate) to give a ketone compound [XXIII], followed by subjecting it to a catalytic reduction in the presence of a suitable catalyst (e.g. palladium-carbon) in a suitable solvent to give the desired o-acylaniline compound [XIV]. Moreover, when the protecting group(s) in $R^5 - R^9$ is/are removed by a catalytic reduction, the product may be again introduced with a protecting group to give an o-acylaniline compound [XIV]. Besides, an o-acylaniline compound [XIV] wherein R^5 is a lower alkyl group may also be prepared by treating a hydroxyl compound [XXII] wherein R^5 is a lower alkenyl group with an oxidizing agent, followed


15

20

by catalytic reduction.

Furthermore, the hydroxyl compound [XXII] wherein the groups R⁵-
R⁹ have a protected amino group, a protected lower alkylamino group, a
protected piperazino group, or a protected hydroxy group may also be prepared
5 by introducing a protecting group to the corresponding compound having
unprotected group(s) by a conventional method.

The 2-halo-2-indolidinyllacetic ester compound [III] used in the
present invention is novel and can be prepared by a process as shown in the
following reaction scheme-2.

Reaction Scheme-2


wherein R¹, R², X and E are as defined above.

That is, an indolidine compound [XXIV] is reacted with a 1,3-propanediol compound [XXV] in the presence of an acid (e.g. p-toluenesulfonic acid) or a Lewis acid (e.g. trimethylsilyl chloride) to give an indolidinylmethane compound [XXVI], and the compound [XXVI] is treated with a carboxylic diester [XXVII] in the presence of a base (e.g. sodium hydride, potassium t-butoxide) in a suitable solvent (e.g. toluene, tetrahydrofuran) to give a 2-

20

indolidinylacetic ester compound [XXVIII], which is further halogenated by a conventional method to give the desired 2-halo-2-indolidinylacetic ester compound [III].

Among the R type nitrogen-containing fused heterocyclic carboxylic acid compounds [IV] or a salt thereof, the nitrogen-containing fused heterocyclic carboxylic acid compound [XIX] or a salt thereof is novel and can be prepared by reacting an N-unsubstituted nitrogen-containing fused heterocyclic carboxylic acid compound of the formula [XXIX]:



wherein R and n are as defined above, or a salt thereof with a sulfonic acid of the formula [XXX]:



15 wherein Y is as defined above, or a reactive derivative or salt thereof by a conventional sulfonamide forming reaction, for example, by reacting a nitrogen-containing fused heterocyclic carboxylic acid compound [XXIX] and a halide (e.g. chloride) of a sulfonic acid [XXX] in the presence of a base (e.g. alkali metal hydroxide).

20 In the present description and claims, the term "S type" means that the absolute configuration at the 2-position of a 2-substituted hydroxy-2-indolidinylbutyric ester compound [II], a 2-substituted hydroxy-2-(6-substituted aminomethylindolidinyl)butyric ester compound [V], a 2-substituted hydroxy-2-

(6-substituted hydroxymethylindolidinyl)butyric ester compound [VI] or a 2-hydroxy-2-(6-hydroxymethylindolidinyl)butyric acid compound [IX] or a salt thereof, or the absolute configuration at the 4-position of a 4-substituted hydroxypyranoidindoline compound [VII], a 4-hydroxypyranoidindoline compound [VIII] or
5 a salt thereof, a 4-hydroxypyranoidindoline compound [X] or a salt thereof, a 4-alkanoyloxy pyranoidindoline compound [XII], or a 4-alkanoyloxy-pyranoidindoline compound [XIII]; and the absolute configuration at the 2-position of a 2-[(R)-N-tosylprolyloxy]-2-indolidinylbutyric ester compound [XXI] are all in "S" configuration.

10 Throughout the present description and claims, the term "lower alkyl" means a straight chain or branched chain alkyl group having 1 to 6 carbon atoms, the term "lower alkanoyl group" and "lower alkanic acid" mean a straight chain or branched chain alkanoyl group and alkanic acid which each have 1 to 7 carbon atoms, respectively. The term "alkylene group" means a straight chain or branched
15 chain alkylene group having 1 to 10 carbon atoms.

EXAMPLES


This invention is illustrated more specifically by the following examples and reference examples but should not be construed to be limited thereto.

Example 1

20 (1) A mixture of ethyl 2-bromo-2-[6-cyano-1,1-(2,2-dimethyl-trimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (22.21 g),

(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (24.70 g) and potassium carbonate (5.11 g) in dimethylformamide (220 ml) is stirred at 60°C for 70 minutes. The reaction mixture is extracted with ethyl acetate, and the extract is washed with a saturated aqueous saline solution and dried over sodium sulfate. After distilling off the solvent under reduced pressure, the residue is purified with a silica gel column chromatography (eluent; chloroform : ethyl acetate = 10 : 1 → 6 : 1) to give ethyl 2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (35.41 g) as a colorless powder.

Yield: 92%



IR (NujolTM, cm⁻¹): 2220, 1750, 1665, 1615


MS (m/z): 738 (MH⁺)

NMR (300MHz, CDCl₃, δ): 0.89 and 0.90 (3H, s), 1.10 and 1.15 (3H, t, J=7Hz), 1.33 and 1.35 (3H, s), 2.45-2.60 (2H, m), 3.25-3.40 (2H, m), 3.61-3.76 (4H, m), 3.95-4.22 (4H, m), 4.58 and 4.68 (1H, d, J=16Hz), 4.72 and 4.75 (1H, d, J=16Hz), 5.22 and 5.29 (1H, dd and t, J=3.6 and 5Hz), 6.01 and 6.04 (1H, s), 6.58 and

6.65 (1H, s), 7.02-7.20 (4H, m), 7.37-7.51 (3H, m), 7.54-7.60 (2H, m), 7.62-7.68 (2H, m), 7.85-7.93 (2H, m)

(2) Ethyl 2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (33.63 g) is dissolved in dry dimethylacetamide-toluene (1 : 1) (330 ml), and thereto is added a 60% oily dispersion of sodium hydride (2.21 g) (1.2 equivalent), and the mixture is stirred at room temperature for 75 minutes. To the mixture is added ethyl iodide (36.5 ml) (10 equivalents), and the mixture is further stirred at room temperature overnight. The reaction mixture is extracted with ethyl acetate, and the extract is washed with an aqueous citric acid solution and an aqueous saturated saline solution, dried over sodium sulfate-magnesium sulfate, and then treated with active carbon (5 g). After distilling off the solvent under reduced pressure, the residue (35.69 g) [the diastereoselectivity of 2S compound and 2R compound = 15.2 : 1.0 (88% d.e.) which is calculated based on the ratio of integral value at the peak of δ : 6.71 and 6.46 in NMR spectrum] is dissolved in acetone (60 ml), and the mixture is stirred at room temperature, and thereto added portionwise hexane (76 ml) and also added a seed crystal of the desired diastereomer. The precipitated crystals are collected by filtration, washed with acetone-hexane (60 : 76)(about 100 ml) to give ethyl (2S)-2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate (26.64 g) as colorless crystals.

Yield: 76%



m.p.: >82°C (gradually decomposed)

$[\alpha]_D^{26}$: -43.3° (c=1.02, chloroform)

IR (Nujol, cm^{-1}): 2220, 1755, 1660, 1615

MS (m/z): 766 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.70 (3H, t, $J=7.5\text{Hz}$), 0.85 (3H, brs), 1.02 (3H, t,

$J=7\text{Hz}$), 1.21 (3H, brs), 2.16-2.55 (4H, m), 3.35 (1H, dd, $J=6.5$ and 16Hz), 3.50

(1H, dd, $J=3$ and 16Hz), 3.55-3.70 (4H, m), 3.70-3.90 (2H, m), 3.93-4.16 (2H, m),

4.68 (1H, d, $J=16\text{Hz}$), 4.76 (1H, d, $J=16\text{Hz}$), 5.37 (1H, dd, $J=3$ and 6.5Hz), 6.71


(1H, s), 7.02-7.10 (1H, m), 7.10-7.20 (3H, m), 7.36-7.50 (3H, m), 7.54-7.59 (2H, m),

7.63-7.68 (2H, m), 7.89-7.96 (2H, m)

(3) Ethyl (2S)-2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate (23.71 g) and Raney nickel (W-4) (49 g) are dissolved in acetic anhydride-acetic acid (460 ml - 190 ml), and the mixture is stirred under hydrogen atmosphere at 50 - 60°C. After completion of the reaction, the catalyst is filtered off, and the filtrate is concentrated under

reduced pressure, and the residue is purified with a silica gel column chromatography (eluent; chloroform : methanol = 100 : 1 $\rightarrow$ 70 : 1 $\rightarrow$ 60 : 1) to give ethyl (2S)-2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]-carbonyloxy]-2-[6-[(acetylamino)methyl]-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate (22.10 g) as a pale yellow powder.

Yield: 87%



$[\alpha]_D^{26}$: -14.9° (c=1.01, chloroform)

IR (Nujol, cm^{-1}): 3405, 3295, 1750, 1660


MS (m/z): 812 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.69 (3H, t, $J=7.5\text{Hz}$), 0.88 (3H, s), 1.02 (3H, t, $J=7\text{Hz}$), 1.24 (3H, s), 1.96 (3H, s), 2.12-2.55 (4H, m), 3.31 (1H, dd, $J=6.5$ and 16Hz), 3.41 (1H, dd, $J=3$ and 16Hz), 3.59 (2H, s), 3.63 (2H, s), 3.84 (1H, dq, $J=11$ and 7Hz), 3.94-4.14 (3H, m), 4.54 (1H, dd, $J=14$ and 5.5Hz), 4.58-4.68 (1H, m), 4.63 (1H, d, $J=15\text{Hz}$), 4.71 (1H, d, $J=15\text{Hz}$), 5.25 (1H, dd, $J=3$ and 6.5Hz), 6.74 (1H, s), 7.00-7.19 (5H, m), 7.37-7.50 (3H, m), 7.54-7.64 (4H, m), 7.83-7.89 (2H, m)

(4) Ethyl (2S)-2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-

3-isoquinolyl]carbonyloxy]-2-[6-[(acetylamino)methyl]-1,1-(2,2-dimethyl-
 trimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate (30.16 g) is
 dissolved in acetic anhydride-acetic acid (450 ml - 150 ml), and thereto is added
 sodium nitrite (13.18 g) under ice cooling, and the mixture is stirred on an ice-
 5 water bath for 4 hours. The reaction mixture is poured onto chloroform (1.5
 liter), and undissolved substances are filtered off. The filtrate is evaporated to
 dryness under reduced pressure, and the residue is mixed with ethyl acetate
 (900 ml), and the mixture is stirred at 60°C for 13 hours. The reaction mixture is
 diluted with ethyl acetate (700 ml), and the mixture is washed with water and
 10 saline solution, dried over sodium sulfate and then treated with active carbon.
 After distilling off the solvent under reduced pressure, the residue is crystallized
 from ethyl acetate-hexane to give ethyl (2S)-2-[[[(3R)-N-(4-biphenylsulfonyl)-
 1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-acetoxymethyl-1,1-(2,2-
 dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate
 15 (16.77 g) as colorless prisms.

Yield: 55%



m.p.: 145-148°C

$[\alpha]_D^{27}$: -9.6° (c=1.0, chloroform)

IR (Nujol, cm^{-1}): 1755, 1659, 1614


MS (m/z): 813 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.54 (3H, t, $J=7.4\text{Hz}$), 0.88 (3H, s), 1.08 (3H, t, $J=7.1\text{Hz}$), 1.30 (3H, s), 2.09 (3H, s), 2.24 (2H, q like, $J=7.6\text{Hz}$), 2.47 (2H, t, $J=7\text{Hz}$), 3.27 (2H, m), 3.65 (4H, m), 3.91-4.17 (4H, m), 4.64 (1H, d, $J=15.6\text{Hz}$), 4.72 (1H, d, $J=15.6\text{Hz}$), 5.13 (1H, dd, $J=5.3$ and 3Hz), 5.25 (2H, s), 6.65 (1H, s), 7.01-7.20 (4H, m), 7.37-7.50 (3H, m), 7.55-7.59 (2H, m), 7.65 (2H, d like, $J=8.6\text{Hz}$), 7.90 (2H, d like, $J=8.6\text{Hz}$)

(5) Ethyl (2S)-2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-acetoxymethyl-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate (1.457 g) is dissolved in a 80% aqueous trifluoroacetic acid solution (15 ml) under ice cooling, and the mixture is stirred at room temperature for 2 days. The reaction mixture is concentrated under reduced pressure, and the residue is extracted with chloroform, and the extract is washed with water, and dried over magnesium sulfate. The extract is distilled to remove the solvent under reduced pressure to give (4S)-7,8-dihydro-4-ethyl-4-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-1H-pyrano[3,4-f]indolidine-3,6,10(4H)-trione (1.145 g) as a colorless foam.

Yield: 100%

35



IR (Nujol, cm^{-1}): 1746, 1661

MS (m/z): 639 (MH^+)


NMR (300MHz, CDCl_3 , δ): 0.82 (3H, t, $J=7.5\text{Hz}$), 1.78-2.09 (4H, m), 2.66-2.90 (2H, m), 3.23 (2H, d like, $J=4.6\text{Hz}$), 4.07-4.27 (2H, m), 4.53 (1H, d, $J=15.4\text{Hz}$), 4.69 (1H, d, $J=15.6\text{Hz}$), 5.01 (1H, t, $J=5.2\text{Hz}$), 5.23 (1H, d, $J=18\text{Hz}$), 5.49 (1H, d, $J=17.9\text{Hz}$), 6.58 (1H, s), 7.01-7.18 (4H, m), 7.38-7.56 (5H, m), 7.62 (2H, d like, $J=8.6\text{Hz}$), 7.89 (2H, d like, $J=8.6\text{Hz}$)

(6) (4S)-7,8-Dihydro-4-ethyl-4-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-1H-pyrano[3,4-f]indolidine-3,6,10(4H)-trione (1.145 g) and 1-[5'-(3''-(t-butoxycarbonylamino)propyloxy)-2'-aminophenyl]propan-1-one (867 mg) are dissolved in acetic acid (15 ml), and the mixture is stirred at 60°C for 47 hours. The reaction mixture is concentrated under reduced pressure, and the resulting crude product is purified with a silica gel column chromatography (eluent; chloroform : ethyl acetate = 2 : 1 $\rightarrow$ 1 : 1) and then recrystallized from ethyl acetate-hexane to give (20S)-7-ethyl-10-[3-(tert-butoxycarbonylamino)propyloxy]-20-O-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyl]camptothecin (1.11 g) as colorless

crystals.

Yield: 67%

5



m.p.: 213-216°C

IR (Nujol, cm^{-1}): 3407, 1763, 1753, 1709, 1669, 1614

10

MS (m/z): 925 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.86 (3H, t, $J=7.5\text{Hz}$), 1.35 (3H, t, $J=7.6\text{Hz}$), 1.46 (9H, s), 1.88-2.18 (4H, m), 2.94-3.20 (2H, m), 3.34 (2H, d, $J=4.8\text{Hz}$), 3.42 (2H, q like, $J=6.4\text{Hz}$), 4.22 (2H, t, $J=6\text{Hz}$), 4.57 (1H, d, $J=15.4\text{Hz}$), 4.73-4.81 (1H, br), 4.81 (1H, d, $J=15.4\text{Hz}$), 4.90 (1H, d, $J=18.7\text{Hz}$), 5.09 (1H, d, $J=18.7\text{Hz}$), 5.21 (1H, d, $J=4.8\text{Hz}$), 5.26 (1H, d, $J=17.2\text{Hz}$), 5.51 (1H, d, $J=17.2\text{Hz}$), 6.99 (1H, s), 7.01-7.18 (4H, m), 7.22-7.29 (2H, m), 7.30-7.42 (6H, m), 7.49 (1H, dd, $J=9.3$ and 2.7Hz), 7.89 (2H, d like, $J=8.6\text{Hz}$), 8.20 (1H, d, $J=9.2\text{Hz}$)

15


(7) (20S)-7-Ethyl-10-[3-(tert-butoxycarbonylamino)propyloxy]-20-

O-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyl]-

20

camptothecin (991 mg) is dissolved in water-methanol (6 ml - 30 ml), and thereto is added lithium hydroxide monohydrate (180 mg) under ice cooling, and the mixture is stirred at room temperature for 22 hours and further stirred at 50°C

for 4 hours. The reaction mixture is concentrated under reduced pressure, and thereto are added chloroform (20 ml) and acetic acid (4 ml), and the mixture is stirred at room temperature for 19 hours. The reaction mixture is diluted with chloroform and water, and the chloroform layer is washed with water and an aqueous saturated saline solution, dried over sodium sulfate. The solvent is distilled off under reduced pressure to give (20S)-7-ethyl-10-[3-(tert-butoxycarbonylamino)propyloxy]camptothecin.




(8) The obtained (20S)-7-ethyl-10-[3-(tert-butoxycarbonylamino)-

propyloxy]camptothecin is dissolved in water-ethanol (5 ml - 15 ml) and thereto is added 6.6N hydrochloric acid-ethanol (5 ml), and the mixture is stirred at room temperature for 23 hours. The reaction mixture is evaporated to dryness under reduced pressure and the residue is dissolved in ethyl acetate and water. The ethyl acetate layer is further extracted with water, and the aqueous layers are combined and evaporated to dryness under reduced pressure. The residue is crystallized from isopropanol-water to give (20S)-7-ethyl-10-(3-aminopropyl-oxy)camptothecin hydrochloride (240 mg) as pale yellow needles.

Yield: 44% overall in the above (7) and (8)

38



m.p.: >218°C (decomposed)

5 $[\alpha]_D^{25}$: +9.8° (c=1.0, water)

MS (m/z): 450 (M-Cl⁺)

IR (Nujol, cm⁻¹): 3450, 3370, 1745, 1660


NMR (300MHz, DMSO-d₆, δ): 0.88 (3H, t, J=7Hz), 1.32 (3H, t, J=8Hz), 1.78-1.95

(2H, m), 2.08-2.19 (2H, m), 3.0-3.1 (2H, m), 3.13-3.25 (2H, m), 4.32 (2H, t, J=6Hz),

10 5.32 (2H, s), 5.43 (2H, s), 7.28 (1H, s), 7.50-7.56 (2H, m), 7.99 (3H, brs), 8.11 (1H, d, J=10Hz)


Example 2

(1) The (4S)-7,8-dihydro-4-ethyl-4-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-1H-pyrano[3,4-f]indolidine-3,6,10(4H)-trione obtained in Example 1-(5) is treated in the same manner as described in Example 1-(7) to give (4S)-7,8-dihydro-4-ethyl-4-hydroxy-1H-pyrano[3,4-f]indolidine-3,6,10(4H)-trione.



(2) The (4S)-7,8-dihydro-4-ethyl-4-hydroxy-1H-pyrano[3,4-f]indolidine-3,6,10(4H)-trione is treated in the same manner as described in


5



10

15

20



IR (Nujol, cm^{-1}): 2225, 1750, 1665, 1615

MS (m/z): 707 (MH⁺)


NMR (300MHz, CDCl₃, δ): 0.89 and 0.90 (3H, s), 1.10 and 1.20 (3H, t, J=7Hz),
1.33 and 1.36 (3H, s), 2.54-2.63 (2H, m), 3.30-3.42 (2H, m), 3.60-3.75 (4H, m),
4.00-4.22 (4H, m), 4.50 and 4.57 (1H, d, J=15Hz), 4.78 and 4.83 (1H, d, J=15Hz),
5.22 and 5.32 (1H, dd, J=3 and 6Hz), 5.90 and 5.95 (1H, s), 6.48 and 6.54 (1H, s),
7.00-7.23 (4H, m), 8.01 and 8.05 (2H, d, J=9Hz), 8.29 and 8.31 (2H, d, J=9Hz)

(2) Ethyl 2-[[[(3R)-N-(4-nitrophenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (25.09 g) is dissolved in dry
dimethylacetamide-toluene (1 : 1) (240 ml), and the mixture is reacted in the
same manner as described in Example 1-(2) using a 60% oily dispersion of
sodium hydride (1680 mg) (1.2 equivalent) and ethyl iodide (54.58 g) (10
equivalents), and the extract is washed with an aqueous citric acid solution and
an aqueous saturated saline solution, dried over magnesium sulfate. After
distilling off the solvent under reduced pressure, the residue is powdered from
ethyl acetate - diethyl ether to give ethyl 2-[[[(3R)-N-(4-nitrophenylsulfonyl)-
1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-dimethyl-
trimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate
(diastereomer mixture) (22.04 g) as a colorless powder. The diastereoselectivity
of 2S compound and 2R compound = 20.0 : 1.0 (90% d.e.) which is calculated
based on the ratio of integral value at the peak of δ : 6.85 and 6.41 in NMR
spectrum. The colorless powders are recrystallized from isopropanol to give a

pure product (19.32 g) as colorless crystals.

Yield: 75%

5



m.p.: 181-182°C

$[\alpha]_D^{26}$: -128.39° (c=0.5, chloroform)

10

IR (Nujol, cm^{-1}): 2217, 1755, 1665, 1615

MS (m/z): 735 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.77 (3H, t, $J=7.5\text{Hz}$), 0.85 (3H, s), 0.89 (3H, t,

$J=7\text{Hz}$), 1.20 (3H, s), 2.13 (1H, dq, $J=7.3$ and 15Hz), 2.27 (1H, dq, $J=7.3$ and

15Hz), 2.52-2.57 (2H, m), 3.45-3.66 (7H, m), 3.80-3.90 (1H, m), 4.16 (1H, dq,

15


$J=7.3$ and 13Hz), 4.36 (1H, dq, $J=7.3$ and 13Hz), 4.52 (1H, d, $J=15\text{Hz}$), 4.87 (1H,

d, $J=15\text{Hz}$), 5.48 (1H, dd, $J=3$ and 6Hz), 6.85 (1H, s), 7.00-7.10 (1H, m), 7.12-7.23

(3H, m), 8.05 (2H, d, $J=9\text{Hz}$), 8.24 (2H, d, $J=9\text{Hz}$)

(3) The compound obtained in (2) above is treated in the same manner as described in Example 1-(3)-(8) or in Example 1-(3)-(5), (7), (6) and (8) to give (20S)-7-ethyl-10-(3-aminopropoxy)camptothecin hydrochloride.


20



Example 4

(1) Ethyl 2-bromo-2-[6-cyano-1,1-(2,2-diethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (363 mg), (3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (472 mg) and potassium carbonate (95 mg) are mixed in dimethylformamide (4 ml), and the mixture is stirred at 70°C for 40 minutes. The reaction mixture is treated in the same manner as described in Example 1-(1) to give ethyl 2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-diethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (579 mg) as a colorless powder.


Yield=94%

IR (Nujol, cm^{-1}): 2225, 1750, 1665, 1615MS (m/z): 766 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.84 (3H, t, $J=7.5\text{Hz}$), 0.94 (3H, t, $J=7.5\text{Hz}$), 1.11 and 1.16 (3H, t, $J=7\text{Hz}$), 1.20-1.30 (2H, m), 1.77-1.86 (2H, m), 2.45-2.60 (2H, m), 3.27-

3.40 (2H, m), 3.60-3.65 (2H, m), 3.75-3.90 (2H, m), 4.00-4.20 (4H, m), 4.55 and 4.80 (2H, m), 5.21 and 5.28 (1H, dd, $J=3$ and 6Hz), 6.02 and 6.06 (1H, s), 6.57 and 6.63 (1H, s), 7.00-7.20 (4H, m), 7.40-7.70 (7H, m), 7.88 and 7.90 (2H, d, $J=8$ Hz)

5 (2) Ethyl 2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-diethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (564 mg) is dissolved in dry dimethyl-
formamide (5 ml), and the mixture is reacted in the same manner as described in
Example 1-(2) using a 60% oily dispersion of sodium hydride (35 mg)(1.2
10 equivalent) and ethyl iodide (1150 mg) (10 equivalents) to give ethyl 2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-diethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-
indolidinyl]butyrate (diastereomer mixture) (522 mg) as a colorless powder. The
diastereoselectivity of 2S compound and 2R compound = 10.8 : 1.0 (83% d.e.)
15 which is calculated based on the ratio of integral value at the peak of δ : 6.67 and 6.43 in NMR spectrum.




20 IR (Nujol, cm^{-1}): 2220, 1750, 1660, 1615

MS (m/z): 794 (MH^+)

NMR (300MHz, CDCl₃, δ): 0.69 (3H, t, J=7.5Hz), 0.81 (3H, t, J=7.5Hz), 0.87 (3H, t, J=7.5Hz), 1.03 (3H, t, J=7Hz), 1.22 (2H, q, J=7.5Hz), 1.67 (2H, q, J=7.5Hz), 2.20-2.45 (4H, m), 3.34 (1H, dd, J=6.5 and 16Hz), 3.48-3.58 (3H, m), 3.70-3.85 (4H, m), 3.98-4.10 (2H, m), 4.67 (1H, d, J=15Hz), 4.76 (1H, d, J=15Hz), 5.36 (1H, dd, J=3 and 6.5Hz), 6.43 and 6.67 (1H, s), 7.00-7.20 (4H, m), 7.40-7.50 (3H, m), 7.56 (2H, d, J=8Hz), 7.65 (2H, d, J=9Hz), 7.92 (2H, d, J=9Hz)


(3) The compound obtained in (2) above is treated in the same manner as described in Example 1-(3)-(8) or in Example 1-(3)-(5), (7), (6) and (8) to give (20S)-7-ethyl-10-(3-aminopropoxy)camptothecin hydrochloride.



Example 5

(1) Ethyl (2S)-2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-acetoxymethyl-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate obtained in Example 1-(4) (1.00 g) is dissolved in water-methanol-tetrahydrofuran (5 ml + 20 ml + 5 ml), and thereto is added lithium hydroxide monohydrate (265 mg), and the mixture is stirred at room temperature for one hour to give lithium (2S)-2-hydroxy-2-[6-hydroxymethyl-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate.


45



(2) Lithium (2S)-2-hydroxy-2-[6-hydroxymethyl-1,1-(2,2-dimethyl-

5 trimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate obtained above is dissolved in chloroform (20 ml) and acetic acid (4 ml), and the mixture is stirred at room temperature for 16 hours, and to the reaction mixture is added water, and the mixture is extracted with chloroform three times. The extract is washed with an aqueous saturated saline solution, dried over sodium sulfate,
10 and distilled under reduced pressure. The residue is purified by silica gel column chromatography (eluent, chloroform) and recrystallized from ethyl acetate to give (4S)-7,8-dihydro-4-ethyl-6,6-(2,2-dimethyltrimethylenedioxy)-4-hydroxy-1H-pyrano[3,4-f]indolidine-3,10-dione (276 mg) as colorless needles.

Yield: 64% over all in (1) and (2) above



m.p.: 208-210°C


20 $[\alpha]_D^{27}$: +88.2° (c=0.99, chloroform)

IR (Nujol, cm^{-1}): 3340, 2924, 1744


MS (m/z): 350 (MH^+)

NMR (300MHz, CDCl₃, δ): 0.88 (3H, s), 0.99 (3H, t, J=7.3Hz), 1.29 (3H, s), 1.70-1.92 (2H, m), 2.54 (2H, t, J=7.0Hz), 3.65-3.69 (4H, m), 3.71 (1H, s), 4.14 (2H, dt, J=3.7 and 7.0Hz), 5.17 (1H, d, J=16.2Hz), 5.60 (1H, d, J=16.2Hz), 6.81 (1H, s)

(3) The (4S)-7,8-dihydro-4-ethyl-6,6-(2,2-dimethyltrimethylene-dioxy)-4-hydroxy-1H-pyrano[3,4-f]indolidine-3,10-dione is treated in the same manner as described in Example 1-(5) to give (4S)-7,8-dihydro-4-ethyl-4-hydroxy-1H-pyrano[3,4-f]indolidine-3,6,10(4H)-trione.




(4) The (4S)-7,8-dihydro-4-ethyl-4-hydroxy-1H-pyrano[3,4-f]-indolidine-3,6,10(4H)-trione is treated in the same manner as described in Example 1-(6) and (8) to give (20S)-7-ethyl-10-(3-aminopropoxy)-camptothecin hydrochloride.




Example 6

(1) Lithium (2S)-2-hydroxy-2-[6-hydroxymethyl-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]butyrate obtained in Example 5-(1) is treated in the same manner as described in Example 1-(5) to give (4S)-7,8-dihydro-4-ethyl-4-hydroxy-1H-pyrano[3,4-f]indolidine-3,6,10(4H)-trione.




(2) The (4S)-7,8-dihydro-4-ethyl-4-hydroxy-1H-pyrano[3,4-f]indolizidine-3,6,10(4H)-trione is treated in the same manner as described in Example 1-(6) and (8) to give (20S)-7-ethyl-10-(3-aminopropoxy)-camptothecin hydrochloride.



Example 7

(1) The (4S)-7,8-dihydro-4-ethyl-6,6-(2,2-dimethyltrimethylenedioxy)-4-hydroxy-1H-pyrano[3,4-f]indolizidine-3,10-dione obtained in Example 5-(2) (50 mg) is dissolved in acetic anhydride (1 ml), and thereto are added pyridine (1 ml) and 4-N,N-dimethylaminopyridine (4 mg) under ice cooling, and the mixture is stirred at room temperature for 23 hours. The reaction mixture is diluted with chloroform, and the mixture is washed with an aqueous citric acid solution, water and an aqueous saturated saline solution, and dried over sodium sulfate. After distilling off the solvent under reduced pressure, the residue is purified by silica gel column chromatography (eluent, chloroform : methanol = 40 : 1) to give (4S)-7,8-dihydro-4-ethyl-6,6-(2,2-dimethyltrimethylenedioxy)-4-acetoxy-1H-pyrano[3,4-f]indolizidine-3,10-dione (56 mg) as colorless crystals.

Yield: 99%




m.p.: 185-188°C

IR (Nujol, cm^{-1}): 2922, 2852, 1743, 1671, 1613

MS (m/z): 392 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.87 (3H, s), 0.91 (3H, t, $J=7.5\text{Hz}$), 1.28 (3H, s), 1.95-2.10 (1H, m), 2.15 (3H, s), 2.15-2.28 (1H, m), 2.40-2.61 (2H, m), 3.55-3.73 (4H, m), 4.12 (2H, t, $J=6.8\text{Hz}$), 5.27 (1H, d, $J=17.1\text{Hz}$), 5.52 (1H, d, $J=17\text{Hz}$), 6.31 (1H, s)

(2) The (4S)-7,8-dihydro-4-ethyl-6,6-(2,2-dimethyltrimethylene-dioxy)-4-acetoxy-1H-pyrano[3,4-f]indolidine-3,10-dione is treated in the same manner as described in Example 1-(5) to give (4S)-7,8-dihydro-4-ethyl-4-acetoxy-1H-pyrano[3,4-f]indolidine-3,6,10(4H)-trione as colorless crystals.



m.p.: 197-203°C


IR (Nujol, cm^{-1}): 1742, 1732, 1661, 1610

ESI-MS (0.02M ammonium acetate/methanol, m/z): 323 (MNH_4^+)

NMR (300MHz, CDCl_3 , δ): 0.92 (3H, t, $J=7.5\text{Hz}$), 1.94-2.25 (2H, m), 2.16 (3H, s), 2.95 (2H, t, $J=6.9\text{Hz}$), 4.32 (2H, td, $J=6.9$ and 0.8Hz), 5.33 (1H, dd, $J=18.1$ and

0.5Hz), 5.60 (1H, dd, J=18.1 and 0.4Hz), 6.76 (1H, s)

(3) The (4S)-7,8-dihydro-4-ethyl-4-acetoxy-1H-pyrano[3,4-f]-indolidine-3,6,10(4H)-trione is treated in the same manner as described in Example 1-(6) to give (20S)-20-O-acetyl-7-ethyl-10-[3-(tert-butoxycarbonyl-amino)propyloxy]camptothecin as a colorless powder.



m.p.: 173-176°C


IR (Nujol, cm^{-1}): 3370, 1765, 1749, 1696, 1657

ESI-MS (m/z): 592 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.97 (3H, t, J=7.5Hz), 1.39 (3H, t, J=7.7Hz), 1.45 (9H, s), 2.05-2.32 (4H, m), 2.21 (3H, s), 3.14 (2H, q, J=7.7Hz), 3.41 (2H, q like, J=6.3Hz), 4.21 (2H, t, J=6.1Hz), 4.77 (1H, br), 5.23 (2H, d, J=1.1Hz), 5.40 (1H, d, J=17.2Hz), 5.68 (1H, d, J=17.2Hz), 7.15 (1H, s), 7.33 (1H, d, J=2.6Hz), 7.47 (1H, dd, J=9.2 and 2.7Hz), 8.12 (1H, d, J=9.3Hz)

(4) The (20S)-20-O-acetyl-7-ethyl-10-[3-(tert-butoxycarbonylamino)-propyloxy]camptothecin is treated in the same manner as described in Example 1-(7) and (8) to give (20S)-7-ethyl-10-(3-aminopropyloxy)camptothecin hydrochloride.




50



Examples 8 - 12

- 5 (1) The corresponding starting compounds are treated in the same manner as described in Example 1-(1) and (2), to prepare the compounds as shown in the following Table 1.

Table 1






Ex. No.		
	X	Diastereoselectivity 2S:2R
8 (1)	-Cl	9.5 : 1.0
9 (1)	-CH ₃	9.0 : 1.0
10 (1)	-OCH ₃	9.0 : 1.0
11 (1)		9.5 : 1.0
12 (1)		10.1 : 1.0

(2) The compounds obtained in (1) above are treated in the same manner as described in Example 1-(3)-(8) or Example 1-(3)-(5), (7), (6) and (8) to give (20S)-7-ethyl-10-(3-aminopropyloxy)camptothecin hydrochloride.

Examples 13 - 16

(1) The corresponding starting compounds are treated in the same manner as described in Example 1-(1) and (2), to prepare the compounds as shown in the following Table 2.

Table 2

Ex. No.	
	R ⁰
13 (1)	
14 (1)	
15 (1)	
16 (1)	

Ts: Tosyl group


5

(2) The compounds obtained in (1) above are treated in the same manner as described in Example 1-(3)-(8) or Example 1-(3)-(5), (7), (6) and (8) to give (20S)-7-ethyl-10-(3-aminopropoxy)camptothecin hydrochloride.

Examples 17 - 23

The corresponding starting compounds are treated in the same manner as described in Examples 1, 2, 5 or 7, to prepare the compounds as shown in the following Table 3.

Table 3

Ex. No.					
	R ⁵¹	R ⁶¹	R ⁷¹	R ⁸¹	R ⁹¹
17	$-\text{CH}_2-\text{N} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{NH}$	-H	$-\text{O}(\text{CH}_2)_2\text{O}-$		-H
18	$-\text{CH}_2\text{NH}_2$	-H	$-\text{O}(\text{CH}_2)_2\text{O}-$		-H
19	$-\text{CH}_2\text{NH}_2$	-H	$-\text{OCH}_2\text{O}-$		-H
20	-H	$-\text{NH}_2$	-H	-H	-H
21	$\begin{array}{cc} 7^* & 9^* \\ -\text{CH}(\text{NH}_2)\text{CH}_2\text{CH}_2- \end{array}$		$-\text{CH}_3$	-F	-H
22	$-(\text{CH}_2)_3-$		$-\text{O}(\text{CH}_2)_3\text{NH}_2$	-H	-H
23	-H	-H	$-\text{O}(\text{CH}_2)_3\text{NH}_2$	-H	-H

*: The number means the substitution position (7-position/9-position) at the camptothecin nucleus.

Example 24

(1) A mixture of ethyl 2-chloro-2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (34.11 g), (3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (42.33 g) and potassium carbonate (8.67 g) in dimethylformamide (350 ml) is stirred at 60°C for 45 minutes. The reaction mixture is ice-cooled, diluted with ethyl acetate (200 ml), and thereto is added an aqueous saturated sodium hydrogen carbonate solution (300 ml) and is further added water (500 ml). The mixture is extracted with ethyl acetate, and the extract is washed, dried, treated with active carbon and filtered. The solvent is distilled off to give ethyl 2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (66.20 g) as a pale yellow foam.

IR (Nujol, cm^{-1}): 2220, 1750, 1665, 1615

MS (m/z): 738 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.89 and 0.90 (3H, s), 1.10 and 1.15 (3H, t, $J=7\text{Hz}$), 1.33 and 1.35 (3H, s), 2.45-2.60 (2H, m), 3.25-3.40 (2H, m), 3.61-3.76 (4H, m), 3.95-4.22 (4H, m), 4.58 and 4.68 (1H, d, $J=16\text{Hz}$), 4.72 and 4.75 (1H, d, $J=16\text{Hz}$), 5.22 and 5.29 (1H, dd and t, $J=3.6$ and 5Hz), 6.01 and 6.04 (1H, s), 6.58 and 6.65 (1H, s), 7.02-7.20 (4H, m), 7.37-7.51 (3H, m), 7.54-7.60 (2H, m), 7.62-7.68 (2H, m), 7.85-7.93 (2H, m)

(2) The ethyl 2-[[[(3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolyl]carbonyloxy]-2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-

oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate obtained in (1) above is treated in the same manner as described in Example 1-(2)-(8) to give (20S)-7-ethyl-10-(3-aminopropoxy)camptothecin hydrochloride.

Reference Example 1

5 (1) 6-Cyano-7-methyl-1,5-dioxo-1,2,3,5-tetrahydroindolidine (1.0 g), 2,2-dimethyl-1,3-propanediol (6.64 g) and p-toluenesulfonic acid (15 ml) are mixed in dichloroethane (25 ml), and the mixture is heated under reflux for 17 hours with a reflux apparatus provided with a Dean-Stark dehydrating device. The reaction mixture is washed with an aqueous saturated sodium hydrogen
10 carbonate solution and an aqueous saturated saline solution, and dried over magnesium sulfate. After distilling off the solvent under reduced pressure, the residue is purified with a silica gel column chromatography (eluent; chloroform : methanol = 50 : 1) and recrystallized from methanol to give 6-cyano-7-methyl-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydroindolidine (1.05 g)
15 as colorless needles.

Yield: 72%

m.p.: 225-226°C

IR (Nujol, cm^{-1}): 2222, 1645, 1610

MS (m/z): 275 (MH^+)

20 NMR (300MHz, CDCl_3 , δ): 0.87 (3H, s), 1.30 (3H, s), 2.49 (3H, s), 2.53 (2H, t, $J=7\text{Hz}$), 3.62 (2H, d, $J=11\text{Hz}$), 3.69 (2H, d, $J=11\text{Hz}$), 4.15 (2H, t, $J=7\text{Hz}$), 6.42 (1H, s)

(2) The 6-cyano-7-methyl-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydroindolidine (14.43 g) is mixed in dry toluene (300 ml) and thereto is added a 60% oily dispersion of sodium hydride (9.26 g, 4.4 equivalents), and the mixture is stirred on a bath of 80°C for 2 hours. To the reaction mixture are added diethyl carbonate (24.85 g, 4 equivalents) and ethanol (0.97 g, 0.4 equivalent), and the mixture is reacted at 80°C for 3 hours. While cooling the reaction mixture on an ice bath, a 50% acetic acid (80 ml) is added thereto. The mixture is extracted with chloroform, and the extract is washed with an aqueous saturated saline solution, and dried over magnesium sulfate. After distilling off the solvent under reduced pressure, the residue is purified with a silica gel column chromatography (eluent; chloroform : ethyl acetate = 4 : 1) and recrystallized from ethyl acetate-ether to give ethyl 2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7--indolidinyl]acetate (14.63 g) as colorless needles.

Yield: 80%

m.p.: 150-151°C

IR (Nujol, cm^{-1}): 2220, 1725, 1650, 1610

MS (m/z): 347 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.87 (3H, s), 1.28 (3H, s), 1.29 (3H, t, $J=7.5\text{Hz}$), 2.54 (2H, t, $J=7\text{Hz}$), 3.62 (2H, d, $J=11\text{Hz}$), 3.68 (2H, d, $J=11\text{Hz}$), 3.79 (2H, s), 4.16 (2H, t, $J=7\text{Hz}$), 4.22 (2H, q, $J=7\text{Hz}$), 6.54 (1H, s)

(3) The ethyl 2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-

1,2,3,5-tetrahydro-7-indolidinyl]acetate (14.60 g) is added to a suspension of a 60% oily dispersion of sodium hydride (2.02 g, 1.2 equivalent) in dry tetrahydrofuran (240 ml), and the mixture is stirred at room temperature for 3 hours. To the reaction mixture is added bromine (8.76 g, 1.3 equivalent), and the mixture is stirred at room temperature for 2 hours, and thereto is added ice water. The mixture is extracted with chloroform, and the extract is washed with an aqueous sodium thiosulfate solution and an aqueous saturated saline solution, and dried over magnesium sulfate. After distilling off the solvent under reduced pressure, the residue is purified with a silica gel column chromatography (eluent; chloroform : ethyl acetate = 4 : 1) and recrystallized from ethyl acetate-ether to give ethyl 2-bromo-2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (15.66 g) as colorless needles.

Yield: 87%

m.p.: 117-119°C

IR (Nujol, cm^{-1}): 2217, 1725, 1650, 1610

MS (m/z): 427 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.89 (3H, s), 1.28 (3H, s), 1.32 (3H, t, $J=7\text{Hz}$), 2.54 (2H, t, $J=7\text{Hz}$), 3.65 (2H, d, $J=12\text{Hz}$), 3.67 (2H, d, $J=12\text{Hz}$), 4.09-4.22 (2H, m), 4.24-4.35 (2H, m), 5.61 (1H, s), 6.90 (1H, s)

Reference Example 2

(1) 6-Cyano-7-methyl-1,5-dioxo-1,2,3,5-tetrahydroindolidine (5.93 g), 2,2-diethyl-1,3-propanediol (49.97 g) and p-toluenesulfonic acid (180 ml) are

mixed in dichloroethane (150 ml), and the mixture is heated under reflux for 22 hours with a reflux apparatus provided with a Dean-Stark dehydrating device. The reaction mixture is treated in the same manner as described in Reference Example 1-(1) and recrystallized from methanol to give 6-cyano-7-methyl-1,1-(2,2-diethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydroindolidine (6.67 g) as colorless needles.

Yield: 70%

m.p.: 197-198°C

IR (Nujol, cm^{-1}): 2219, 1655, 1610

MS (m/z): 303 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.83 (3H, t, $J=7.5\text{Hz}$), 0.92 (3H, t, $J=7.5\text{Hz}$), 1.22 (2H, q, $J=7.5\text{Hz}$), 1.78 (2H, q, $J=7.5\text{Hz}$), 2.49 (3H, s), 2.52 (2H, t, $J=7\text{Hz}$), 3.64 (2H, d, $J=11\text{Hz}$), 3.78 (2H, d, $J=11\text{Hz}$), 4.14 (2H, t, $J=7\text{Hz}$), 6.39 (1H, s)

(2) The procedure of Reference Example 1-(2) is repeated using 6-cyano-7-methyl-1,1-(2,2-diethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydroindolidine (4.75 g), dry toluene (80 ml), a 60% oily dispersion of sodium hydride (2.76 g, 4.4 equivalents), diethyl carbonate (7.42 g, 4 equivalents) and ethanol (0.37 ml, 0.4 equivalent), and the product is recrystallized from ethyl acetate-ether to give ethyl 2-[6-cyano-1,1-(2,2-diethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (3.71 g) as colorless needles.

Yield: 63%

m.p.: 127-129°C

IR (Nujol, cm^{-1}): 2220, 1745, 1660, 1605

MS (m/z): 375 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.83 (3H, t, $J=7.5\text{Hz}$), 0.91 (3H, t, $J=7.5\text{Hz}$), 1.23 (2H, q, $J=7.5\text{Hz}$), 1.29 (3H, t, $J=7.5\text{Hz}$), 1.75 (2H, q, $J=7.5\text{Hz}$), 2.53 (2H, t, $J=7\text{Hz}$),
5 3.62 (2H, d, $J=12\text{Hz}$), 3.77 (2H, d, $J=12\text{Hz}$), 3.79 (2H, s), 4.15 (2H, t, $J=7\text{Hz}$), 4.22
(2H, q, $J=7\text{Hz}$), 6.50 (1H, s)

(3) The ethyl 2-[6-cyano-1,1-(2,2-diethyltrimethylenedioxy)-5-oxo-
1,2,3,5-tetrahydro-7-indolidinyl]acetate (3.52 g) is added to a suspension of a
60% oily dispersion of sodium hydride (451 mg, 1.2 equivalent) in dry tetra-
10 hydrofuran (60 ml), and the mixture is treated at room temperature for 3 hours.
To the reaction mixture is added bromine (1.95 g, 1.3 equivalent), and the
mixture is stirred at room temperature for 3 hours, and the reaction mixture is
treated in the same manner as described in Reference Example 1-(3) and
recrystallized from ethyl acetate-ether to give ethyl 2-bromo-2-[6-cyano-1,1-
15 (2,2-diethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate
(2.45 g) as colorless needles.

Yield: 58%

m.p.: 106-108°C

IR (Nujol, cm^{-1}): 2220, 1735, 1660, 1610

20 MS (m/z): 455 (MH^+)

NMR (300MHz, CDCl_3 , δ): 0.83 (3H, t, $J=7.5\text{Hz}$), 0.92 (3H, t, $J=7.5\text{Hz}$), 1.26 (2H, q, $J=7.5\text{Hz}$), 1.32 (3H, t, $J=7\text{Hz}$), 1.73 (2H, q, $J=7.5\text{Hz}$), 2.52 (2H, t, $J=7\text{Hz}$), 3.61

(1H, d, J=12Hz), 3.62 (1H, d, J=12Hz), 3.77 (1H, dd, J=2 and 12Hz), 3.80 (1H, dd, J=2 and 12Hz), 4.16 (2H, m), 4.25-4.35 (2H, m), 5.61 (1H, s), 6.85 (1H, s)

Reference Example 3

Sodium hydroxide (13.6 g) is dissolved in water (300 ml), and therein
5 is suspended (3R)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (30.0 g) and
thereto is added tetrahydrofuran (120 ml). To the resulting solution is added 4-
biphenylsulfonyl chloride (42.9 g), and the mixture is stirred at room
temperature for one hour. The reaction mixture is acidified with 10% hydro-
chloric acid under ice cooling, and is diluted with water, and then extracted
10 twice with ethyl acetate. The extract is washed with water and an aqueous
saturated saline solution, dried over sodium sulfate and then treated with active
carbon. Undissolved materials are filtered off from the extract, and the solvent is
distilled off under reduced pressure. The residue is recrystallized from ethyl
acetate-hexane to give (3R)-N-(4-biphenylsulfonyl)-1,2,3,4-tetrahydro-3-
15 isoquinolinecarboxylic acid (36.5 g) as colorless crystals.

Yield: 55%

m.p.: 195-202°C

$[\alpha]_{D^{29}}$: +8.02° (c=1.08, dimethylformamide)

IR (Nujol, cm⁻¹): 3300, 2924, 1743, 1456

20 MS (m/z): 394 (MH⁺)

NMR (300MHz, CDCl₃, δ): 3.10-3.15 (2H, m), 4.48 (1H, d, J=15.6Hz), 4.67 (1H, d, J=15.6Hz), 4.93 (1H, dd, J=4.0 and 5.3Hz), 6.95-7.20 (4H, m), 7.40-7.53 (3H, m),

7.56-7.69 (4H, m), 7.83-7.88 (2H, m)

Reference Example 4

(3R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid (5.32 g) and sodium hydroxide (2.40 g) are added to a mixture of methylene chloride-water (200 ml - 200 ml), and thereto is added dropwise a solution of 4-nitrophenylsulfonyl chloride (6.62 g) in methylene chloride (100 ml) under ice cooling over a period of 30 minutes. The mixture is stirred under ice cooling for 3 hours, and thereto are further added sodium hydroxide (1.20 g) and a solution of 4-nitrophenylsulfonyl chloride (3.32 g) in methylene chloride (60 ml) in this order. The mixture is stirred under ice cooling for 2 hours, and further stirred at room temperature for 17 hours, and the reaction mixture is diluted with chloroform and 10% hydrochloric acid. The chloroform layer is collected and washed with water and then with an aqueous saturated saline solution, dried over sodium sulfate and then treated with active carbon. Undissolved materials are filtered off from the chloroform layer, and the solvent is distilled off under reduced pressure. The residue is purified with a silica gel column chromatography (eluent, chloroform) and recrystallized from ethyl acetate-hexane to give (3R)-N-(4-nitrophenylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (4.01 g) as colorless crystals.

Yield: 37%

m.p.: 140°C

$[\alpha]_D^{25}$: +27.2° (c=0.5, ethanol)

IR (Nujol, cm⁻¹): 3316, 1743, 1531, 1169

MS (m/z): 361 (M-H⁺)

NMR (300MHz, CDCl₃, δ): 3.15-3.30 (2H, m), 4.40 (1H, d, J=15Hz), 4.73 (1H, d, J=15Hz), 5.01 (1H, dd, J=3.7 and 5.7Hz), 7.04-7.20 (4H, m), 7.99 (2H, d, J=9.0Hz), 8.20 (2H, d, J=9.0Hz)

5 Reference Example 5

To a suspension of ethyl 2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (43.41 g) in tetrahydrofuran (600 ml) is added triethylamine (13.94 g) under argon atmosphere at -4°C and thereto is further added dropwise trimethylsilyl chloride (14.41 g) at -4 to
10 -3°C over a period of 5 minutes. The mixture is stirred at the same temperature for 55 minutes and thereto is added dropwise a suspension of N-chlorosuccinimide (17.00 g) in tetrahydrofuran (400 ml) at -4 to 4°C over a period of 7 minutes. The reaction mixture is further stirred at a temperature of 0°C to 4°C for 4.5 hours, and thereto added water (1 liter) at 0°C, and the mixture is
15 extracted with ethyl acetate. The extract is washed, dried, treated with active carbon, filtered and then distilled to remove the solvent. The residue is recrystallized from ethyl acetate-isopropyl ether to give ethyl 2-chloro-2-[6-cyano-1,1-(2,2-dimethyltrimethylenedioxy)-5-oxo-1,2,3,5-tetrahydro-7-indolidinyl]acetate (40.28 g) as colorless needles.

20 Yield: 84%

m.p.: 153-155°C

IR (Nujol, cm⁻¹): 2227, 1749, 1662, 1615, 1541, 1311, 1241, 1202, 1179, 1161,

1143, 1065, 967, 835, 715

APCIMS (m/z): 381 and 383 (MH⁺)

NMR (300MHz, CDCl₃, δ): 0.88 (3H, s), 1.28 (3H, s), 1.31 (3H, t, J=7.1Hz), 2.52-
2.58 (2H, m), 3.60-3.70 (4H, m), 4.13-4.21 (2H, m), 4.22-4.37 (2H, m), 5.63 (1H,s),
5 6.77 (1H, s)

Reference Example 6

(1) 3-Aminopropanol (6.0 g) is dissolved in methylene chloride (50 ml) and thereto is added dropwise di-t-butyl dicarbonate (18.3 g) with stirring under ice cooling. The mixture is stirred at room temperature for 2 hours, and
10 the reaction mixture is concentrated and then purified with a silica gel column chromatography to give 3-t-butoxycarbonylaminopropanol (13.98 g) as a colorless oil.

Yield: 99.9%

IR (Neat), $\nu_{\max}$ cm⁻¹: 3380, 1790

15 MS (m/z): 176 (M+H⁺)

NMR (300MHz, CDCl₃, δ): 1.45 (9H, s), 1.62-1.72 (2H, m), 3.0 (1H, brs.), 3.29
(2H, dd, J=12Hz and 6Hz), 3.66 (2H, dd, J=12Hz and 6Hz), 4.80 (1H, brs)

(2) 3-t-Butoxycarbonylaminopropanol (10.0 g) is dissolved in methylene chloride (100 ml) and thereto are added triethylamine (8.66 g) and
20 tosyl chloride (16.3 g) with stirring under ice cooling. The mixture is stirred at room temperature overnight. The reaction mixture is concentrated and the residue is dissolved in water-ethyl acetate, and the organic layer is separated,

washed with an aqueous saturated saline solution, dried over sodium sulfate, and then the solvent is distilled off. The residue is purified with a silica gel column chromatography to give 3-t-butoxycarbonylaminopropyl tosylate (15.37 g) as a pale yellow oil.

5 Yield: 82%

IR (Neat), $\nu_{\max}$ cm^{-1} : 3400, 3340, 1700, 1600

MS (m/z): 352 (M+Na⁺)

NMR (300MHz, CDCl₃, δ): 1.42 (9H, s), 1.78-1.90 (2H, m), 2.45 (3H, s), 3.11-3.22 (2H, m), 4.09 (2H, t, J=6Hz), 4.5-4.65 (1H, m), 7.36 (2H, d, J=8Hz), 7.77-7.83 (2H, m)

10

(3) 5-Hydroxy-2-nitrobenzaldehyde (6.0 g) is dissolved in dry tetrahydrofuran (90 ml) and thereto is added dropwise vinylmagnesium bromide (2.3 equivalents) with stirring at -78°C. The temperature of the reaction mixture is raised gradually. After completion of the reaction, 1N HCl is added to the reaction mixture, and the mixture is extracted with ethyl acetate, and the organic layer is separated, washed with an aqueous saturated saline solution, dried over sodium sulfate, and then the solvent is distilled off. The residue is purified with a silica gel column chromatography to give 1-(5'-hydroxy-2'-nitrophenyl)-2-propen-1-ol (5.09 g) as a yellowish brown powder.

15

20

Yield: 73%

m.p.: 126-130°C

IR (Nujol), $\nu_{\max}$ cm^{-1} : 3440, 1600

MS (m/z): 195 (M⁺)

NMR (300MHz, CDCl₃, δ): 2.4 (1H, br), 5.19 (1H, dd, J=10.5Hz and 1.5Hz), 5.38 (1H, dd, J=17Hz and 1.5Hz), 5.89 (1H, m), 6.08 (1H, ddd, J=17Hz, 10.5Hz and 5Hz), 6.80 (1H, dd, J=9Hz and 3Hz), 7.22 (1H, d, J=3Hz), 7.97 (1H, d, J=9Hz), 9.90 (1H, brs)

(4) 1-(5'-Hydroxy-2'-nitrophenyl)-2-propen-1-ol (2.0 g) is dissolved in dry dimethylformamide (100 ml) and thereto are added sodium iodide (1 equivalent) and potassium carbonate and 3-t-butoxycarbonylaminopropyl tosylate (1.5 equivalent). The mixture is stirred at 50°C for 6 hours, and thereto is added ethyl acetate. The mixture is washed with an aqueous saturated saline solution, dried over sodium sulfate. After distilling off the solvent, the residue is purified with a silica gel column chromatography to give 1-[5'-(3''-t-butoxycarbonylaminopropoxy)-2'-nitrophenyl]-2-propen-1-ol (3.53 g) as a pale brown sticky product.

Yield: 98%

IR (Neat), $\nu_{\max}$ cm⁻¹: 3400, 1690, 1680

MS (m/z): 375 (M+Na⁺)

NMR (300MHz, CDCl₃, δ): 1.44 (9H, s), 1.96-2.06 (2H, m), 2.80 (1H, brs), 3.33 (2H, q, J=6.5Hz), 4.11 (2H, t, J=6Hz), 4.8 (1H, brs), 5.24 (1H, dd, J=10.5Hz and 1.5Hz), 5.42 (1H, dd, J=17Hz and 1.5Hz), 5.92 (1H, d, J=5Hz), 6.08 (1H, ddd, J=17Hz, 10.5Hz and 5Hz), 6.86 (1H, dd, J=9Hz and 3Hz), 7.25 (1H, d, J=3Hz), 8.04 (1H, d, J=9Hz)

(5) 1-[5'-(3"-t-Butoxycarbonylaminopropyloxy)-2'-nitrophenyl]-2-propen-1-ol (9.66 g) is dissolved in chloroform (300 ml) and thereto is added activated manganese dioxide (7.2 g), and the mixture is heated with reflux. After completion of the reaction, inorganic materials are filtered off with CeliteTM, and the filtrate is concentrated, and thereto is added ethyl acetate. The organic layer is separated, washed with an aqueous saturated saline solution, dried over sodium sulfate. After distilling off the solvent, the residue is purified with a silica gel column chromatography to give 1-[5'-(3"-t-butoxycarbonylaminopropyl-oxy)-2'-nitrophenyl]-2-propen-1-one (6.01 g) as yellow color crystals.

m.p.: 65-71°C

Yield: 63%

IR (Neat), $\nu_{\max}$ cm⁻¹: 3350, 1700

MS (m/z): 351 (M+H⁺)

NMR (300MHz, CDCl₃, δ): 1.44 (9H, s), 1.98-2.18 (2H, m), 3.28-3.37 (2H, q, J=6.5Hz), 4.08-4.16 (2H, m), 4.67 (1H, brs), 5.85 (1H, d, J=17.5Hz), 6.02 (1H, d, J=10.5Hz), 6.62 (1H, dd, J=17.5Hz and 10.5Hz), 6.82 (1H, d, J=3Hz), 7.03 (1H, dd, J=9Hz and 3Hz), 8.17 (1H, d, J=9Hz)

(6) 1-[5'-(3"-t-Butoxycarbonylaminopropyloxy)-2'-nitrophenyl]-2-propen-1-one (325 mg) is dissolved in ethanol (15 ml) and thereto is added 10% palladium-carbon (40 mg), and the mixture is stirred under hydrogen atmosphere for 1.5 hours. After removing the catalyst by filtration, the filtrate is concentrated and purified with a silica gel column chromatography to give 1-[5'-(3"-t-butoxy-

carbonylaminopropoxy)-2'-aminophenyl]propan-1-one (248 mg) as a yellow powder.

m.p.: 112-115°C

Yield: 83%

5 IR (Nujol), $\nu_{\max}$ cm^{-1} : 3450, 3400, 3340, 1700, 1650

MS (m/z): 323 (M+H⁺)

NMR (300MHz, CDCl₃, δ): 1.21 (3H, t, J=7Hz), 1.45 (9H, s), 1.90-2.01 (2H, m),


2.95 (2H, q, J=7.5Hz), 3.33 (2H, q, J=6.5Hz), 3.97 (2H, t, J=6.5Hz), 4.48 (1H,

brs), 5.96 (2H, brs), 6.62 (1H, d, J=9Hz), 6.95 (1H, dd, J=9Hz and 3Hz), 7.24 (1H,


10 d, J=3Hz)

CLAIMS:

1. A process for preparing an S type 2-substituted hydroxy-2-indolidinylbutyric ester compound of the formula [II]:




wherein R⁰ is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:




wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₃₋₆ cycloalkyl group, a halogen atom, and a thienyl group), or C₁₋₆ alkylsulfonyl group, and n is 0 or 1, R¹ and R² are each a C₁₋₆ alkyl group, and E is a C₁₋₆ alkyl group,

which comprises (a) ethylating a 2-substituted hydroxy-2-indolidinylacetic ester compound of the formula [I]:



wherein R⁰, R¹ and R² and E are as defined above,

at the 2-position thereof, or (b) reacting a 2-halo-2-indolidinylacetic ester compound of the formula [III]:




wherein X is a halogen atom, and R¹, R² and E are as defined above,

with an R type nitrogen-containing fused heterocyclic carboxylic acid compound of the formula [IV]:




- 5 wherein R⁰ is as defined above, or a salt thereof to give a 2-substituted hydroxy-2-indolidinylacetic ester compound of the formula [I]:




wherein R⁰, R¹, R² and E are as defined above, and then ethylating the 2-position of the resultant compound [I].

2. A process for preparing an S type 4-substituted hydroxypyrano-indolidine compound of the formula [VII]:
- 10




wherein R^0 is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:

5



10 wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{3-6} cycloalkyl group, a halogen atom, and a thienyl group), or C_{1-6} alkylsulfonyl group, and n is 0 or 1, which comprises subjecting the S type 2-


15 substituted hydroxy-2-indolidinylbutyric ester compound of the formula [II]:




20

wherein R^0 is as defined above, and R^1 and R^2 are each a C_{1-6} alkyl group, and E is a C_{1-6} alkyl group, obtained in claim 1 to a catalytic reduction to reduce the cyano group thereof and then subjecting to alkanoylation to give an S type 2-substituted

hydroxy-2-(6-substituted aminomethylindolidinyl) butyric ester compound of the formula (V):



wherein R³ is a C₁₋₇ alkanoyl group, and R⁰, R¹, R² and E are as defined above,
 5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
 110
 115
 120
 125
 130
 135
 140
 145
 150
 155
 160
 165
 170
 175
 180
 185
 190
 195
 200
 205
 210
 215
 220
 225
 230
 235
 240
 245
 250
 255
 260
 265
 270
 275
 280
 285
 290
 295
 300
 305
 310
 315
 320
 325
 330
 335
 340
 345
 350
 355
 360
 365
 370
 375
 380
 385
 390
 395
 400
 405
 410
 415
 420
 425
 430
 435
 440
 445
 450
 455
 460
 465
 470
 475
 480
 485
 490
 495
 500
 505
 510
 515
 520
 525
 530
 535
 540
 545
 550
 555
 560
 565
 570
 575
 580
 585
 590
 595
 600
 605
 610
 615
 620
 625
 630
 635
 640
 645
 650
 655
 660
 665
 670
 675
 680
 685
 690
 695
 700
 705
 710
 715
 720
 725
 730
 735
 740
 745
 750
 755
 760
 765
 770
 775
 780
 785
 790
 795
 800
 805
 810
 815
 820
 825
 830
 835
 840
 845
 850
 855
 860
 865
 870
 875
 880
 885
 890
 895
 900
 905
 910
 915
 920
 925
 930
 935
 940
 945
 950
 955
 960
 965
 970
 975
 980
 985
 990
 995
 1000
 1005
 1010
 1015
 1020
 1025
 1030
 1035
 1040
 1045
 1050
 1055
 1060
 1065
 1070
 1075
 1080
 1085
 1090
 1095
 1100
 1105
 1110
 1115
 1120
 1125
 1130
 1135
 1140
 1145
 1150
 1155
 1160
 1165
 1170
 1175
 1180
 1185
 1190
 1195
 1200
 1205
 1210
 1215
 1220
 1225
 1230
 1235
 1240
 1245
 1250
 1255
 1260
 1265
 1270
 1275
 1280
 1285
 1290
 1295
 1300
 1305
 1310
 1315
 1320
 1325
 1330
 1335
 1340
 1345
 1350
 1355
 1360
 1365
 1370
 1375
 1380
 1385
 1390
 1395
 1400
 1405
 1410
 1415
 1420
 1425
 1430
 1435
 1440
 1445
 1450
 1455
 1460
 1465
 1470
 1475
 1480
 1485
 1490
 1495
 1500
 1505
 1510
 1515
 1520
 1525
 1530
 1535
 1540
 1545
 1550
 1555
 1560
 1565
 1570
 1575
 1580
 1585
 1590
 1595
 1600
 1605
 1610
 1615
 1620
 1625
 1630
 1635
 1640
 1645
 1650
 1655
 1660
 1665
 1670
 1675
 1680
 1685
 1690
 1695
 1700
 1705
 1710
 1715
 1720
 1725
 1730
 1735
 1740
 1745
 1750
 1755
 1760
 1765
 1770
 1775
 1780
 1785
 1790
 1795
 1800
 1805
 1810
 1815
 1820
 1825
 1830
 1835
 1840
 1845
 1850
 1855
 1860
 1865
 1870
 1875
 1880
 1885
 1890
 1895
 1900
 1905
 1910
 1915
 1920
 1925
 1930
 1935
 1940
 1945
 1950
 1955
 1960
 1965
 1970
 1975
 1980
 1985
 1990
 1995
 2000
 2005
 2010
 2015
 2020
 2025
 2030
 2035
 2040
 2045
 2050
 2055
 2060
 2065
 2070
 2075
 2080
 2085
 2090
 2095
 2100
 2105
 2110
 2115
 2120
 2125
 2130
 2135
 2140
 2145
 2150
 2155
 2160
 2165
 2170
 2175
 2180
 2185
 2190
 2195
 2200
 2205
 2210
 2215
 2220
 2225
 2230
 2235
 2240
 2245
 2250
 2255
 2260
 2265
 2270
 2275
 2280
 2285
 2290
 2295
 2300
 2305
 2310
 2315
 2320
 2325
 2330
 2335
 2340
 2345
 2350
 2355
 2360
 2365
 2370
 2375
 2380
 2385
 2390
 2395
 2400
 2405
 2410
 2415
 2420
 2425
 2430
 2435
 2440
 2445
 2450
 2455
 2460
 2465
 2470
 2475
 2480
 2485
 2490
 2495
 2500
 2505
 2510
 2515
 2520
 2525
 2530
 2535
 2540
 2545
 2550
 2555
 2560
 2565
 2570
 2575
 2580
 2585
 2590
 2595
 2600
 2605
 2610
 2615
 2620
 2625
 2630
 2635
 2640
 2645
 2650
 2655
 2660
 2665
 2670
 2675
 2680
 2685
 2690
 2695
 2700
 2705
 2710
 2715
 2720
 2725
 2730
 2735
 2740
 2745
 2750
 2755
 2760
 2765
 2770
 2775
 2780
 2785
 2790
 2795
 2800
 2805
 2810
 2815
 2820
 2825
 2830
 2835
 2840
 2845
 2850
 2855
 2860
 2865
 2870
 2875
 2880
 2885
 2890
 2895
 2900
 2905
 2910
 2915
 2920
 2925
 2930
 2935
 2940
 2945
 2950
 2955
 2960
 2965
 2970
 2975
 2980
 2985
 2990
 2995
 3000
 3005
 3010
 3015
 3020
 3025
 3030
 3035
 3040
 3045
 3050
 3055
 3060
 3065
 3070
 3075
 3080
 3085
 3090
 3095
 3100
 3105
 3110
 3115
 3120
 3125
 3130
 3135
 3140
 3145
 3150
 3155
 3160
 3165
 3170
 3175
 3180
 3185
 3190
 3195
 3200
 3205
 3210
 3215
 3220
 3225
 3230
 3235
 3240
 3245
 3250
 3255
 3260
 3265
 3270
 3275
 3280
 3285
 3290
 3295
 3300
 3305
 3310
 3315
 3320
 3325
 3330
 3335
 3340
 3345
 3350
 3355
 3360
 3365
 3370
 3375
 3380
 3385
 3390
 3395
 3400
 3405
 3410
 3415
 3420
 3425
 3430
 3435
 3440
 3445
 3450
 3455
 3460
 3465
 3470
 3475
 3480
 3485
 3490
 3495
 3500
 3505
 3510
 3515
 3520
 3525
 3530
 3535
 3540
 3545
 3550
 3555
 3560
 3565
 3570
 3575
 3580
 3585
 3590
 3595
 3600
 3605
 3610
 3615
 3620
 3625
 3630
 3635
 3640
 3645
 3650
 3655
 3660
 3665
 3670
 3675
 3680
 3685
 3690
 3695
 3700
 3705
 3710
 3715
 3720
 3725
 3730
 3735
 3740
 3745
 3750
 3755
 3760
 3765
 3770
 3775
 3780
 3785
 3790
 3795
 3800
 3805
 3810
 3815
 3820
 3825
 3830
 3835
 3840
 3845
 3850
 3855
 3860
 3865
 3870
 3875
 3880
 3885
 3890
 3895
 3900
 3905
 3910
 3915
 3920
 3925
 3930
 3935
 3940
 3945
 3950
 3955
 3960
 3965
 3970
 3975
 3980
 3985
 3990
 3995
 4000
 4005
 4010
 4015
 4020
 4025
 4030
 4035
 4040
 4045
 4050
 4055
 4060
 4065
 4070
 4075
 4080
 4085
 4090
 4095
 4100
 4105
 4110
 4115
 4120
 4125
 4130
 4135
 4140
 4145
 4150
 4155
 4160
 4165
 4170
 4175
 4180
 4185
 4190
 4195
 4200
 4205
 4210
 4215
 4220
 4225
 4230
 4235
 4240
 4245
 4250
 4255
 4260
 4265
 4270
 4275
 4280
 4285
 4290
 4295
 4300
 4305
 4310
 4315
 4320
 4325
 4330
 4335
 4340
 4345
 4350
 4355
 4360
 4365
 4370
 4375
 4380
 4385
 4390
 4395
 4400
 4405
 4410
 4415
 4420
 4425
 4430
 4435
 4440
 4445
 4450
 4455
 4460
 4465
 4470
 4475
 4480
 4485
 4490
 4495
 4500
 4505
 4510
 4515
 4520
 4525
 4530
 4535
 4540
 4545
 4550
 4555
 4560
 4565
 4570
 4575
 4580
 4585
 4590
 4595
 4600
 4605
 4610
 4615
 4620
 4625
 4630
 4635
 4640
 4645
 4650
 4655
 4660
 4665
 4670
 4675
 4680
 4685
 4690
 4695
 4700
 4705
 4710
 4715
 4720
 4725
 4730
 4735
 4740
 4745
 4750
 4755
 4760
 4765
 4770
 4775
 4780
 4785
 4790
 4795
 4800
 4805
 4810
 4815
 4820
 4825
 4830
 4835
 4840
 4845
 4850
 4855
 4860
 4865
 4870
 4875
 4880
 4885
 4890
 4895
 4900
 4905
 4910
 4915
 4920
 4925
 4930
 4935
 4940
 4945
 4950
 4955
 4960
 4965
 4970
 4975
 4980
 4985
 4990
 4995
 5000
 5005
 5010
 5015
 5020
 5025
 5030
 5035
 5040
 5045
 5050
 5055
 5060
 5065
 5070
 5075
 5080
 5085
 5090
 5095
 5100
 5105
 5110
 5115
 5120
 5125
 5130
 5135
 5140
 5145
 5150
 5155
 5160
 5165
 5170
 5175
 5180
 5185
 5190
 5195
 5200
 5205
 5210
 5215
 5220
 5225
 5230
 5235
 5240
 5245
 5250
 5255
 5260
 5265
 5270
 5275
 5280
 5285
 5290
 5295
 5300
 5305
 5310
 5315
 5320
 5325
 5330
 5335
 5340
 5345
 5350
 5355
 5360
 5365
 5370
 5375
 5380
 5385
 5390
 5395
 5400
 5405
 5410
 5415
 5420
 5425
 5430
 5435
 5440
 5445
 5450
 5455
 5460
 5465
 5470
 5475
 5480
 5485
 5490
 5495
 5500
 5505
 5510
 5515
 5520
 5525
 5530
 5535
 5540
 5545
 5550
 5555
 5560
 5565
 5570
 5575
 5580
 5585
 5590
 5595
 5600
 5605
 5610
 5615
 5620
 5625
 5630
 5635
 5640
 5645
 5650
 5655
 5660
 5665
 5670
 5675
 5680
 5685
 5690
 5695
 5700
 5705
 5710
 5715
 5720
 5725
 5730
 5735
 5740
 5745
 5750
 5755
 5760
 5765
 5770
 5775
 5780
 5785
 5790
 5795
 5800
 5805
 5810
 5815
 5820
 5825
 5830
 5835
 5840
 5845
 5850
 5855
 5860
 5865
 5870
 5875
 5880
 5885
 5890
 5895
 5900
 5905
 5910
 5915
 5920
 5925
 5930
 5935
 5940
 5945
 5950
 5955
 5960
 5965
 5970
 5975
 5980
 5985
 5990
 5995
 6000
 6005
 6010
 6015
 6020
 6025
 6030
 6035
 6040
 6045
 6050
 6055
 6060
 6065
 6070
 6075
 6080
 6085
 6090
 6095
 6100
 6105
 6110
 6115
 6120
 6125
 6130
 6135
 6140
 6145
 6150
 6155
 6160
 6165
 6170
 6175
 6180
 6185
 6190
 6195
 6200
 6205
 6210
 6215
 6220
 6225
 6230
 6235
 6240
 6245
 6250
 6255
 6260
 6265
 6270
 6275
 6280
 6285
 6290
 6295
 6300
 6305
 6310
 6315
 6320
 6325
 6330
 6335
 6340
 6345
 6350
 6355
 6360
 6365
 6370
 6375
 6380
 6385
 6390
 6395
 6400
 6405
 6410
 6415
 6420
 6425
 6430
 6435
 6440
 6445
 6450
 6455
 6460
 6465
 6470
 6475
 6480
 6485
 6490
 6495
 6500
 6505
 6510
 6515
 6520
 6525
 6530
 6535
 6540
 6545
 6550
 6555
 6560
 6565
 6570
 6575
 6580
 6585
 6590
 6595
 6600
 6605
 6610
 6615
 6620
 6625
 6630
 6635
 6640
 6645
 6650
 6655
 6660
 6665
 6670
 6675
 6680
 6685
 6690
 6695
 6700
 6705
 671




wherein R⁰, R¹, R², R³ and E are as defined above,


subjecting the compound [VI] to an intramolecular cyclization reaction, and

thereafter or at the same time as the cyclization reaction converting the acetal group thereof into a ketone group.

- 5 3. A process for preparing an S type 4-hydroxypyranoidindoline compound of the formula [VIII]:




or a salt thereof, which comprises (a) subjecting the S type 4-substituted hydroxypyranoidindoline compound of the formula [VII]:



wherein R^0 is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:


5



[XIX]


wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{3-6} cycloalkyl group, a halogen atom, and a thienyl group), or C_{1-6} alkylsulfonyl group, and n is 0 or 1, obtained in claim 2 to removal of the group R^0 , or (b) subjecting the S type 2-substituted hydroxy-2-indolidinylbutyric ester compound of the formula [II]:

15




[II]

wherein R^0 is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:



wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{3-6} cycloalkyl group, a halogen atom, and a thienyl group), or C_{1-6} alkylsulfonyl group, and n is 0 or 1, R^1 and R^2 are each a C_{1-6} alkyl group, and E is a C_{1-6} alkyl group, obtained in claim 1 to a catalytic reduction to reduce the cyano group thereof and then subjecting to alkanoylation to give an S type 2-substituted hydroxy-2-(6-substituted aminomethylindolidinyl)butyric ester compound of the

15 formula [V]:




*C1(C2C(C1)OC(C2)OC3C(C4=CC(=C(C=C4)C(=O)N3CC5C(=C(C=C5)C(=O)OC5)C(C5)C(C)C)OC5)C(C)C)OC3

[VI]

CC[C@H](O)(C(=O)O)S1C=CC(=O)N(C1)C2OCC(R1)CC2(R2)O [IX]


4. A process for preparing an S type 4-alkanoyloxypyranoidindolidine compound of the formula [XIII]:



wherein R^4 is a C_{1-7} alkanoyl group,


which comprises subjecting the S type 2-substituted hydroxy-2-indolidinylbutyric ester

5 compound of the formula [II]:



wherein R^0 is a residue obtained by removing a hydroxy group from the


10 carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:




15 wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{3-6} cycloalkyl group, a halogen atom, and a thienyl group), or C_{1-6} alkylsulfonyl group, and n is 0 or 1, R^1 and R^2 are each a C_{1-6} alkyl group, and E is a

20 C_{1-6} alkyl group,


obtained in claim 1 to a catalytic reduction to reduce the cyano group thereof and then subjecting to alkanoylation to give an S type 2-substituted hydroxy-2-(6-substituted aminomethylindolidinyl)butyric ester compound of the formula [V]:



wherein R³ is a C₁₋₇ alkanoyl group, and R⁰, R¹, R² and E are as defined above, subjecting the compound [V] to nitrosation reaction and rearrangement to give an S type 2-substituted hydroxy-2-(6-substituted hydroxymethylindolidinyl)butyric ester compound of the formula [VI]:




- 5 wherein R⁰, R¹, R², R³ and E are as defined above, subjecting the compound [VI] to an ester hydrolysis to give an S type 2-hydroxy-2-(6-hydroxymethylindolidinyl)butyric acid compound of the formula [IX]:



wherein R¹ and R² are as defined above, or a salt thereof, subjecting the compound [IX] to an intramolecular cyclization

reaction, and if required, converting the product into a salt thereof to give an S type 4-hydroxypyranoidindolidine compound of the formula [X]:



wherein R^1 and R^2 are as defined above,


or a salt thereof, and reacting the compound [X] or a salt thereof with a lower

5 alkanolic acid of the formula [XI]:



wherein R^4 is as defined above,


or a reactive derivative thereof to give an S type 4-alkanoyloxypyranoidindolidine compound of the formula [XII]:



10 wherein R^1 , R^2 and R^4 are as defined above,


and subjecting the compound [XII] to conversion of the acetal group thereof into a ketone group.

5. A process for preparing a camptothecin compound of the formula [XVI]:




wherein the groups $R^{51} - R^{91}$ are each a hydrogen atom, a C_{1-6} alkyl group or an amino- C_{1-6} alkoxy group,

- 5 or a salt thereof, which comprises (a) reacting the S type 4-substituted hydroxy-pyranoindolidine compound of the formula [VII]:




- 10 wherein R^0 is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:



15


wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{3-6} cycloalkyl group, a halogen atom, and a thienyl group), or C_{1-6}

- 20 alkylsulfonyl group, and n is 0 or 1, obtained in claim 2 with an o-acylaniline compound of the formula [XIV]:




wherein the groups $R^5 - R^9$ are each a hydrogen atom, a C_{1-6} alkyl group or a protected amino- C_{1-6} alkoxy group,

to give a camptothecin compound having a substituent on the 20-hydroxy group of the formula [XV]:




5 wherein R^0 and R^5 to R^9 are as defined above,

subjecting the compound [XV] to removal of R^0 group and further, when the groups $R^5 - R^9$ are protected, subjecting to removal of the protecting group, and if required, further conversion into a salt thereof, or (b) reacting the S type 4-hydroxypyran-indolidine compound of the formula [VIII]:




10 or a salt thereof obtained in claim 3 with an o-acylaniline compound of the formula [XIV]:



81


wherein the groups $R^5 - R^9$ are each a hydrogen atom, a C_{1-6} alkyl group or a protected amino- C_{1-6} alkoxy group,

to give a camptothecin compound of the formula [XVII]:




wherein R^5 to R^9 are as defined above,

- 5 and when the groups $R^5 - R^9$ are protected, subjecting the compound [XVII] to removal of the protecting group, and if required, further conversion into a salt thereof, or (c) reacting the S type 4-alkanoyloxypyranoidindoline compound of the formula [XIII]:




wherein R^4 is a C_{1-7} alkanoyl group,

- 10 obtained in claim 4 with an o-acylaniline compound of the formula [XIV]:



wherein the groups $R^5 - R^9$ are each a hydrogen atom, a C_{1-6} alkyl group or a protected amino- C_{1-6} alkoxy group,

to give a camptothecin compound of the formula [XVIII]:




wherein R^4 to R^9 are as defined above,


and subjecting the compound [XVIII] to removal of the group R^4 and further when the groups $R^5 - R^9$ are protected, subjecting to removal of the protecting group, and if
10 required, further conversion into a salt thereof.

6. The process according to any one of claims 1, 2, 3, 4 or 5 wherein Y is a 4-biphenylsulfonyl group, or a 4-nitrophenylsulfonyl group, n is 1, R^1 and R^2 are each a methyl group, R^3 is an acetyl group, X is a chlorine atom or a bromine atom, and E is a methyl or ethyl group.

15 7. A 2-substituted hydroxy-2-indolidinylacetic ester compound of the formula [I]:




20 wherein R^0 is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:




wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₃₋₆ cycloalkyl group, a halogen atom, and a thienyl group), or C₁₋₆ alkylsulfonyl group, and n is 0 or 1, R¹ and R² are each a C₁₋₆ alkyl group, and E is a C₁₋₆ alkyl group.

8. An S type 2-substituted hydroxy-2-indolidinylbutyric ester compound of the formula [II]:




wherein R⁰ is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:




wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₃₋₆ cycloalkyl group, a halogen atom, and a thienyl group), or C₁₋₆ alkylsulfonyl group, and n is 0 or 1, R¹ and R² are each a C₁₋₆ alkyl group, and E is a C₁₋₆ alkyl group.

9. An S type 2-substituted hydroxy-2-(6-substituted aminomethyl-indolidinyl)butyric ester compound of the formula [V]:




wherein R^0 is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:




wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{3-6} cycloalkyl group, a halogen atom, and a thienyl group), or C_{1-6} alkylsulfonyl group, and n is 0 or 1, R^1 and R^2 are each a C_{1-6} alkyl group, E is a C_{1-6} alkyl group, and R^3 is a C_{1-7} alkanoyl group.

15

10. An S type 2-substituted hydroxy-2-(6-substituted hydroxy-methylindolidinyl)butyric ester compound of the formula [VI]:




wherein R^0 is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:




wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{3-6} cycloalkyl group, a halogen atom, and a thienyl group), or C_{1-6} alkylsulfonyl group, and n is 0 or 1, R^1 and R^2 are each a C_{1-6} alkyl group, E is a C_{1-6} alkyl group, and R^3 is a C_{1-7} alkanoyl group.

11. An S type 4-substituted hydroxypyranoidindoline compound of the formula [VII]:



wherein R^0 is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:


20




wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₃₋₆ cycloalkyl group, a halogen atom, and a thienyl group), or C₁₋₆

alkylsulfonyl group, and n is 0 or 1.

12. A compound of the formula:




wherein R⁰ is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:




wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₃₋₆ cycloalkyl group, a halogen atom, and a thienyl group), or C₁₋₆ alkylsulfonyl group, and n is 0 or 1, and R¹ and R² are each a C₁₋₆ alkyl group.

13. A camptothecin compound having a substituent on the 20-hydroxy group of the formula [XV]:




wherein R^0 is a residue obtained by removing a hydroxy group from the carboxyl group of an R type nitrogen-containing fused heterocyclic carboxylic acid of the formula [XIX]:



5 wherein Y is a member selected from the group consisting of a phenylsulfonyl, naphthylsulfonyl and biphenylsulfonyl group (which may be unsubstituted or substituted by a member selected from a nitro group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{3-6} cycloalkyl group, a halogen atom, and a thienyl group), or C_{1-6} alkylsulfonyl group, and n is 0 or 1, and the groups $R^5 - R^9$ are a hydrogen atom, a C_{1-6} alkyl group or a protected amimo- C_{1-6} alkoxy group.

14. The compound according to any one of claims 7, 8, 9, 10, 11, 12 or 13, wherein Y is a 4-bi-phenylsulfonyl group, or a 4-nitrophenylsulfonyl group, n is 1, R^1 and R^2 are each a methyl group, and E is a methyl or ethyl group.


15. An S type 2-hydroxy-2-(6-hydroxymethylindolidinyl)butyric acid compound of the formula [IX]:



20 wherein R^1 and R^2 are each a C_{1-6} alkyl group, or a salt thereof.

16. An S type 4-hydroxypyranoidindolidine compound of the formula [X]:


88



wherein R^1 and R^2 are each a C_{1-6} alkyl group, or a salt thereof.

17. An S type 4-alkanoyloxypyranoidindolidine compound of the formula


5 [XII]:



wherein R^1 and R^2 are each a C_{1-6} alkyl group, and R^4 is a C_{1-7} alkanoyl group.


10 18. An S type 4-alkanoyloxypyranoidindolidine compound of the formula

[XIII]:




15 wherein R^4 is a C_{1-6} alkanoyl group.

19. A 2-halogeno-2-indolidinylacetic ester compound of the formula [III]:




20 wherein X is a halogen atom, R^1 and R^2 are each a C_{1-6} alkyl group, and E is a C_{1-6} alkyl group.

20. An indolidinylmethane compound of the formula [XXVI]:




wherein R^1 and R^2 are each a C_{1-6} alkyl group.

- 5 21. A 2-indolidinylacetic ester compound of the formula [XXVIII]:




wherein R^1 and R^2 are each a C_{1-6} alkyl group, and E is a C_{1-6} alkyl group.

- 10 22. A camptothecin compound of the formula [XVIII]:




wherein R^4 is a C_{1-7} alkanoyl group, and the groups $R^5 - R^9$ are each a hydrogen atom,

- 15 a C_{1-6} alkyl group or a protected amino- C_{1-6} alkoxy group.



[II]



[I]